Peptide Initiative

Research library

Master Citation List

Every study cited on Peptide Initiative, organized by page. Numbers match the inline citations you see in the content; each entry lists the sections where it is cited and links to the original source.

138 pages

Peptide Profiles 138

  • 5-Amino-1MQ5 studies
    View page
    [1]

    Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice

    Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ · 2018

    Cited in: Dosing · adjustment, Is this right for me, Dosing, Effectiveness · signs, FAQ, How to use, Safety, Effectiveness · how it works, Safety · side effects, Effectiveness · timeline, Dosing · timing, Effectiveness · troubleshooting

    View study
    [2]

    Nicotinamide N-methyltransferase Inhibition Mitigates Obesity-Related Metabolic Dysfunctions

    Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H · 2024

    Cited in: Dosing · adjustment, Is this right for me, Dosing, Effectiveness · signs, FAQ, How to use, Safety, Effectiveness · how it works, Safety · side effects, Effectiveness · timeline, Safety · when to stop

    View study
    [3]

    Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice

    Dimet-Wiley A, Wu Q, Wiley JT, Eswar A, Neelakantan H, Savidge T, Watowich SJ · 2022

    Cited in: FAQ

    View study
    [4]

    Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome

    Sun WD, Zhu XJ, Li JJ, et al. · 2024

    Cited in: Is this right for me, FAQ, Effectiveness · how it works

    View study
    [5]

    PubChem Compound Summary: 5-Amino-1-methylquinolinium (CID 950107)

    National Center for Biotechnology Information (NCBI) · 2024

    View study
  • Abarelix4 studies
    View page
    [1]

    GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy

    Patel S, Saxena B, Mehta P · 2024

    View study
    [2]

    Utility of LHRH antagonists for advanced prostate cancer

    Moul JW · 2014

    View study
    [3]

    Gonadotropin-releasing hormone: an update review of the antagonists versus agonists

    Van Poppel H, Klotz L · 2012

    View study
    [4]

    Plenaxis (abarelix for injectable suspension) FDA prescribing information / label

    U.S. Food and Drug Administration · 2003

    Cited in: Dosing

    View study
  • Acetyl Hexapeptide-3 (Argireline)5 studies
    View page
    [1]

    The anti-wrinkle efficacy of argireline in Chinese subjects: a randomized, placebo-controlled study

    Wang Y, et al. · 2013

    Cited in: Dosing

    View study
    [2]

    The anti-wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese subjects

    Wang Y, et al. · 2013

    Cited in: Dosing

    View study
    [3]

    The anti-wrinkle efficacy of Argireline

    Wang Y, et al. · 2013

    View study
    [4]

    A synthetic hexapeptide (Argireline) with antiwrinkle activity

    Blanes-Mira C, et al. · 2002

    View study
    [5]

    The study of cellular cytotoxicity of argireline - an anti-aging peptide

    Grosicki M, et al. · 2014

    View study
  • Adipotide4 studies
    View page
    [1]

    Reversal of obesity by targeted ablation of adipose tissue

    Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W · 2004

    View study
    [2]

    A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

    Barnhart KF, Christianson DR, Hanley PW, et al. · 2011

    Cited in: Dosing

    View study
    [3]

    Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma

    Kolonin MG, Pasqualini R, Arap W · 2011

    View study
    [4]

    Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight

    Kim DH, Woods SC, Seeley RJ · 2010

    View study
  • Adrenomedullin5 studies
    View page
    [1]

    Early Use of Innovative Biomarkers Such as Mid-Regional Pro-Adrenomedullin and SeptiCyte RAPID in Post-Cardiac Surgery Patients: Pilot Case Series

    Risso C, Vay L, Sciascia F · 2025

    View study
    [2]

    The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature

    Sacco MA, Gualtieri S, Cordasco F · 2024

    View study
    [3]

    Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma

    Kitamura K, Kangawa K, Kawamoto M, et al. · 1993

    View study
    [4]

    Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial

    Ashizuka S, Kuroki M, Yamato T, et al. · 2021

    Cited in: Dosing

    View study
    [5]

    Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial

    Kita T, Kaji Y, Kitamura K · 2020

    Cited in: Dosing

    View study
  • Alexamorelin3 studies
    View page
    [1]

    Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans

    Broglio F, Benso A, Gottero C, et al. · 2000

    Cited in: Dosing

    View study
    [2]

    Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry

    Pobee E, Daziani G, Gameli PS · 2025

    View study
    [3]

    Orally active growth hormone secretagogues: state of the art and clinical perspectives

    Ghigo E, Arvat E, Camanni F · 1998

    Cited in: Dosing

    View study
  • Angiotensin (1-7)5 studies
    View page
    [1]

    The joint-local renin-angiotensin system in rheumatoid arthritis and osteoarthritis: mechanistic evidence, disease-specific patterns, and translational perspectives

    Bilgin E, et al. · 2026

    View study
    [2]

    Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection

    Aazar RFM, et al. · 2026

    View study
    [3]

    Exogenous hydrogen sulfide inhibits the progression of vascular dysfunction and hypertension mediated by the renin-angiotensin system in chronic kidney disease

    Tapia-Martínez JA, et al. · 2026

    View study
    [4]

    Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy

    Pham H, Schwartz BM, Delmore JE, et al. · 2013

    Cited in: Dosing

    View study
    [5]

    A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19

    Self WH, Shotwell MS, Gibbs KW, et al. · 2022

    Cited in: Dosing

    View study
  • AOD-96045 studies
    View page
    [1]

    Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone

    Ng FM et al. · 2000

    Cited in: Dosing

    View study
    [2]

    Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

    Heffernan MA et al. · 2001

    View study
    [3]

    The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

    Heffernan M et al. · 2001

    View study
    [4]

    Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

    Kwon DR et al. · 2015

    View study
    [5]

    The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study

    Metabolic Pharmaceuticals; Stier H, et al. · 2007

    Cited in: Dosing

    View study
  • Apelin-134 studies
    View page
    [1]

    Exogenous [Pyr(1)]apelin-13 prevents bupivacaine-induced cardiotoxicity via the apelin (APJ) receptor

    Chen C, Zhao S, Chen Z · 2025

    View study
    [2]

    A Metabolically Stable Apelin-13 Analog Acting as a Potent I(To) Potassium Current Blocker with Potential Benefits for Brugada Syndrome

    Contreras Vite JA, Tiffinger A, Théroux L · 2025

    View study
    [3]

    Apelin/APJ signaling in IGF-1-induced acute mitochondrial and antioxidant effects in spontaneously hypertensive rat myocardium

    Yeves AM, Godoy Coto J, Pereyra EV · 2024

    View study
    [4]

    Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure

    Japp AG, Cruden NL, Barnes G, et al. · 2010

    Cited in: Dosing

    View study
  • ARA-290 (Cibinetide)6 studies
    View page
    [1]

    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

    Brines M, et al. · 2015

    Cited in: Dosing

    View study
    [2]

    Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain

    Culver DA, et al. · 2017

    Cited in: Dosing

    View study
    [3]

    Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy

    Brines M, et al. · 2018

    View study
    [4]

    Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection

    Liu Y, et al. · 2014

    View study
    [5]

    ARA 290 for treatment of small fiber neuropathy in sarcoidosis

    van Velzen M, et al. · 2014

    View study
    [6]

    Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

    Heij L, Niesters M, Swartjes M, et al. · 2012

    Cited in: Dosing

    View study
  • Bestatin (Ubenimex)5 studies
    View page
    [1]

    Ubenimex (Bestatin): Immunomodulator with antitumor activity — overview of clinical studies

    Umezawa H, Ishizuka M, Aoyagi T · 1986

    Cited in: Dosing

    View study
    [2]

    Effect of bestatin on natural killer cell activity and cell-mediated immunity in leukemia patients

    Ota K, Kurita S, Makino N · 1992

    View study
    [3]

    Bestatin as an immunomodulatory agent: effects on bone marrow recovery and T-cell subset populations

    Abe F, Shibuya K, Uchida M · 1990

    View study
    [4]

    Randomized controlled trial of bestatin maintenance therapy in acute non-lymphocytic leukemia

    Hirata Y, Tanimoto M, Ogawa Y · 1991

    Cited in: Dosing

    View study
    [5]

    Leukotriene A4 hydrolase inhibition by bestatin: implications for pulmonary arterial hypertension

    Tian W, Jiang X, Tamosiuniene R · 2013

    View study
  • BPC-1573 studies
    View page
    [1]

    BPC 157 and its role in healing

    Sikiric et al. · 2018

    Cited in: Dosing

    View study
    [2]

    Gastric pentadecapeptide BPC 157 and wound healing

    Seiwerth et al. · 2014

    Cited in: Dosing

    View study
    [3]

    Effect of BPC 157 on tendon healing

    Chang et al. · 2011

    Cited in: Dosing

    View study
  • Buserelin5 studies
    View page
    [1]

    An improved use of buserelin in ovarian stimulation for in-vitro fertilization

    PubMed Central · 1990

    View study
    [2]

    Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety

    Raja T, Sud R, Addla S · 2022

    View study
    [3]

    Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and FDA databases

    Cicione A, Nacchia A, Guercio A · 2023

    View study
    [4]

    Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study

    Chen Y, Lu W, Liao R · 2025

    View study
    [5]

    Product Monograph: SUPREFACT (buserelin acetate) injection and nasal solution, and SUPREFACT DEPOT implant

    Sanofi-aventis Canada Inc. · 2015

    Cited in: Dosing

    View study
  • Cagrilintide5 studies
    View page
    [1]

    Once-weekly cagrilintide for weight management in people with overweight and obesity

    Lau DCW et al. · 2021

    Cited in: Dosing

    View study
    [2]

    Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide

    Enebo LB et al. · 2021

    View study
    [3]

    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

    Garvey WT et al. · 2025

    View study
    [4]

    Development of Cagrilintide, a Long-Acting Amylin Analogue

    Kruse T et al. · 2021

    View study
    [5]

    Efficacy and safety of CagriSema in type 2 diabetes

    Frias JP et al. · 2023

    View study
  • Capromorelin3 studies
    View page
    [1]

    Effects of an oral growth hormone secretagogue (capromorelin) in older adults

    White HK, Petrie CD, Landschulz W, et al. · 2009

    Cited in: Dosing

    View study
    [2]

    Efficacy and safety of capromorelin (Elura) for weight management in cats with chronic kidney disease: a randomized, double-blind, placebo-controlled trial

    Zollers B, et al. · 2020

    View study
    [3]

    Capromorelin acetate as an oral appetite stimulant in companion animals: mechanism, clinical efficacy, and safety profile

    Various veterinary researchers · 2021

    View study
  • Cartalax5 studies
    View page
    [1]

    The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging

    Myakisheva SN, Linkova NS, Diatlova AS · 2023

    View study
    [2]

    Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation

    Myakisheva SN, Linkova NS, Kozhevnikova EO · 2023

    View study
    [3]

    Peptide Regulation of Chondrogenic Stem Cell Differentiation

    Linkova N, Khavinson V, Diatlova A · 2023

    Cited in: Dosing

    View study
    [4]

    Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides

    Ashapkin V, Khavinson V, Shilovsky G · 2020

    Cited in: Dosing

    View study
    [5]

    Tripeptides slow down aging process in renal cell culture

    Khavinson VKh, Tarnovskaia SI, Lin'kova NS · 2014

    View study
  • Cathelicidin (hCAP-18 / Synthetic Derivatives)5 studies
    View page
    [1]

    The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms

    de Breij A, Riool M, Cordfunke RA · 2018

    View study
    [2]

    SAAP-148 Eradicates MRSA Persisters Within Mature Biofilm Models Simulating Prosthetic Joint Infection

    Dijksteel GS, Ulrich MMW, Middelkoop E · 2019

    View study
    [3]

    Cathelicidin antimicrobial peptides in the treatment of infectious diseases and their clinical potential

    Mookherjee N, Anderson MA, Haagsman HP · 2020

    View study
    [4]

    Ototopical drops containing a novel antibacterial synthetic peptide (P60.4Ac/OP-145): safety and efficacy in adults with chronic suppurative otitis media

    Peek NFAW, et al. · 2020

    Cited in: Dosing

    View study
    [5]

    Vitamin D-mediated cathelicidin expression: innate immunity meets antimicrobial defense

    Wang TT, Nestel FP, Bourdeau V · 2004

    View study
  • Cerebrolysin7 studies
    View page
    [1]

    Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

    Gavrilova SI, Alvarez A · 2021

    View study
    [2]

    Role and Impact of Cerebrolysin for Ischemic Stroke Care

    Mureșanu DF, Livinț Popa L, Chira D et al. · 2022

    View study
    [3]

    Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

    Kojder K, Jarosz K, Bosiacki M et al. · 2023

    View study
    [4]

    Neuroprotective strategies of cerebrolysin for the treatment of infants with neonatal hypoxic-ischemic encephalopathy

    Fiani B, Chacon D, Jarrah R et al. · 2021

    View study
    [5]

    The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts

    Al-Kuraishy HM, Al-Gareeb AI, Zekry SH et al. · 2025

    View study
    [6]

    Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial

    Guekht AB et al. · 2011

    Cited in: Dosing

    View study
    [7]

    CASTA: Cerebrolysin in acute ischemic stroke (clinical trial dosing)

    2012

    Cited in: Dosing

    View study
  • Cerluten6 studies
    View page
    [1]

    Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease

    Ilina A, Khavinson V, Linkova N · 2022

    View study
    [2]

    AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism

    Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B · 2020

    View study
    [3]

    Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease

    Kraskovskaya NA, Kukanova EO, Lin'kova NS · 2017

    View study
    [4]

    Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides

    Ashapkin V, Khavinson V, Shilovsky G · 2020

    View study
    [5]

    Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro

    Lin'kova NS, Drobintseva AO, Orlova OA · 2016

    View study
    [6]

    Cerluten (CNS peptide bioregulator) manufacturer usage instructions

    2024

    Cited in: Dosing

    View study
  • Cetrorelix6 studies
    View page
    [1]

    Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF

    Mouanness M, et al. · 2025

    View study
    [2]

    Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation

    Glujovsky D, et al. · 2023

    View study
    [3]

    Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for prevention of ovarian hyperstimulation syndrome

    Qi Q, et al. · 2023

    View study
    [4]

    GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology

    Tur-Kaspa I, et al. · 2009

    View study
    [5]

    CETROTIDE (cetrorelix acetate for injection) FDA Prescribing Information

    2000

    Cited in: Dosing

    View study
    [6]

    DailyMed - CETROTIDE (cetrorelix acetate) kit label

    2024

    Cited in: Dosing

    View study
  • Chonluten6 studies
    View page
    [1]

    Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

    Avolio F, Martinotti S, Khavinson VK · 2022

    View study
    [2]

    Short Peptides Stimulate Hepatocyte Migration and Proliferation through the CXCR4 Receptor

    Khavinson VK, Linkova NS, Diatlova A · 2020

    View study
    [3]

    Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures

    Khavinson VK, Linkova NS, Kvetnoy IM · 2013

    View study
    [4]

    Molecular Aspects of Anti-aging Effect of Short Peptides

    Khavinson VK, Linkova NS, Tarnovskaya SI · 2021

    View study
    [5]

    Geroprotective Effect of Thymalin and Epithalon

    Khavinson VK, Morozov VG · 2003

    View study
    [6]

    Chonluten (bronchopulmonary peptide bioregulator) manufacturer usage instructions

    2024

    Cited in: Dosing

    View study
  • CJC-1295 (No DAC)20 studies
    View page
    [1]

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL et al. · 2006

    Cited in: FAQ, Safety, Effectiveness · timeline

    View study
    [2]

    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

    Ionescu M, Frohman LA · 2006

    Cited in: Is this right for me, Safety, Effectiveness · how it works

    View study
    [3]

    Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse

    Alba M, Fintini D, Sagazio A et al. · 2006

    View study
    [4]

    Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects

    Sackmann-Sala L, Ding J, Frohman LA et al. · 2009

    View study
    [5]

    Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma

    Frohman LA, Downs TR, Heimer EP, Felix AM · 1989

    Cited in: Effectiveness · how it works

    View study
    [6]

    Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences

    Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP · 1994

    Cited in: Effectiveness · how it works

    View study
    [7]

    Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

    Jette L et al. · 2005

    Cited in: Effectiveness · how it works

    View study
    [8]

    Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone

    Mayo KE · 1992

    Cited in: Effectiveness · how it works

    View study
    [9]

    Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level

    Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF · 1995

    Cited in: Is this right for me, Dosing · timing, Effectiveness · troubleshooting

    View study
    [10]

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K, Hansen BS, Johansen NL, et al. · 1998

    Cited in: Dosing · timing, Effectiveness · troubleshooting

    View study
    [11]

    Growth hormone secretion during sleep

    Takahashi Y, Kipnis DM, Daughaday WH · 1968

    Cited in: Effectiveness · how it works

    View study
    [12]

    Interrelationships between growth hormone and sleep

    Van Cauter E, Copinschi G · 2000

    Cited in: Is this right for me, Effectiveness · how it works

    View study
    [13]

    Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls

    Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F · 1992

    Cited in: Is this right for me, Hero

    View study
    [14]

    Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man

    Ghigo E, Miola C, Aimaretti G, Valente F, Procopio M, Arvat E, Yin-Zhang W, Camanni F · 1992

    Cited in: Effectiveness · troubleshooting

    View study
    [15]

    Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects

    Lanzi R, Manzoni MF, Andreotti AC, Malighetti ME, Bianchi E, Sereni LP, Caumo A, Luzi L, Pontiroli AE · 1997

    Cited in: FAQ

    View study
    [16]

    Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men

    Iranmanesh A, Lizarralde G, Veldhuis JD · 1991

    Cited in: Is this right for me, FAQ

    View study
    [17]

    Effects of human growth hormone in men over 60 years old

    Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE · 1990

    Cited in: Is this right for me, FAQ, Hero

    View study
    [18]

    Metabolic effects of a growth hormone-releasing factor in patients with HIV

    Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S · 2007

    Cited in: Is this right for me

    View study
    [19]

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

    Prakash A, Goa KL · 1999

    Cited in: Safety

    View study
    [20]

    Growth hormone deficiency in adults: effects of replacement therapy on body composition and health-related quality of life

    Mesa J, Gomez JM, Hernandez C, Pico A, Ulied A · 2003

    Cited in: Is this right for me, FAQ

    View study
  • CJC-1295 with DAC6 studies
    View page
    [1]

    Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

    Jette L et al. · 2005

    Cited in: Dosing

    View study
    [2]

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL et al. · 2006

    Cited in: Dosing

    View study
    [3]

    Advances in the detection of growth hormone releasing hormone synthetic analogs

    Memdouh S et al. · 2021

    View study
    [4]

    Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography

    Ucakturk E et al. · 2026

    View study
    [5]

    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

    Ionescu M, Frohman LA · 2006

    View study
    [6]

    The safety and efficacy of growth hormone secretagogues

    Sigalos JT, Pastuszak AW · 2018

    View study
  • Copper Tripeptide-1 (GHK-Cu)5 studies
    View page
    [1]

    The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging

    Research investigators · 2020

    View study
    [2]

    Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    Pickart L, Margolina A · 2018

    View study
    [3]

    The human tri-peptide GHK and tissue remodeling

    Pickart L · 2008

    View study
    [4]

    Liposomes as carriers of GHK-Cu tripeptide for cosmetic application

    Research investigators · 2020

    View study
    [5]

    Effect of GHK and GHK-Cu on TGF-β secretion in normal human dermal fibroblasts

    Research investigators · 2020

    View study
  • Cortexin6 studies
    View page
    [1]

    Molecular mechanisms of brain peptide-containing drugs: cortexin

    Gromova OA, Torshin IY, Semenov VA et al. · 2018

    View study
    [2]

    Cortexin: Molecular mechanisms and targets of neuroprotective activity

    Gomazkov OA · 2015

    View study
    [3]

    Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay

    Kurkin DV, Bakulin DA, Morkovin EI et al. · 2025

    View study
    [4]

    Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment and hippocampal changes in chronic brain ischemia

    Tyurenkov IN, Kurkin DV, Kalatanova AV et al. · 2020

    View study
    [5]

    Results of the CORNELia multicenter study evaluating Cortexin and Neuromexol in chronic cerebrovascular pathology with cognitive impairment

    Mashin VV, Belova LA, Kotova EY et al. · 2023

    View study
    [6]

    Cortexin (polypeptide cortex preparation) manufacturer instructions for use

    2020

    Cited in: Dosing

    View study
  • Crystagen6 studies
    View page
    [1]

    Geroprotective Effect of Thymalin and Epithalon

    Khavinson VK, Morozov VG · 2003

    View study
    [2]

    Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice

    Anisimov VN, Khavinson VK, Mikhalski AI · 2001

    View study
    [3]

    Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats

    Anisimov VN, Khavinson VK, Morozov VG · 2000

    View study
    [4]

    Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19

    Khavinson VK, Kuznik BI, Trofimova SV · 2021

    View study
    [5]

    Peptidergic regulation of thymocyte differentiation, proliferation, and apoptosis during aging of the thymus

    Lin'kova NS, Polyakova VO, Trofimov AV · 2011

    View study
    [6]

    Crystagen (immune/thymus peptide bioregulator) manufacturer usage instructions

    2024

    Cited in: Dosing

    View study
  • Daptomycin5 studies
    View page
    [1]

    Daptomycin versus standard-of-care for the treatment of complicated skin and skin-structure infections — Phase III randomized trial

    Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI · 2004

    Cited in: Dosing

    View study
    [2]

    Daptomycin for the treatment of Staphylococcus aureus bacteremia and endocarditis

    Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME · 2006

    Cited in: Dosing

    View study
    [3]

    High-dose daptomycin for persistent MRSA bacteremia: safety and efficacy analysis

    Kullar R, Davis SL, Levine DP, Rybak MJ · 2011

    Cited in: Dosing

    View study
    [4]

    Daptomycin plus ceftaroline combination therapy for persistent MRSA bacteremia — the seesaw effect

    Sakoulas G, Moise PA, Casapao AM, Nonejuie P · 2014

    View study
    [5]

    Mechanism of action of daptomycin: calcium-dependent membrane depolarization and phosphatidylglycerol targeting

    Silverman JA, Perlmutter NG, Shapiro HM · 2003

    View study
  • Defensin (HBD-2)6 studies
    View page
    [1]

    A novel antimicrobial peptide of human skin: isolation, characterization and antimicrobial properties

    Harder J, Bartels J, Christophers E, Schröder JM · 1997

    View study
    [2]

    Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures

    Khavinson VK, Linkova NS, Kvetnoy IM · 2013

    View study
    [3]

    Human beta-defensin-2 expression is increased in chronic wounds

    Butmarc J, Yufit T, Carson P, Bhatt DL, Bhatt DK, Falanga V · 2004

    View study
    [4]

    Human beta-defensin 2 selectively inhibits HIV-1 in activated CD4+ T cells through CCR6-mediated signaling

    Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marber ML, Weinberg A · 2003

    View study
    [5]

    Serum human beta-defensin-2 correlates with disease severity in psoriasis patients

    Jansen PA, Rodijk-Olthuis D, Hollox EJ, Kamsteeg M, Tjabringa GS, de Jongh GJ, van Vlijmen-Willems IM, Bergboer JG, van Rossum MM, de Jong EM, den Heijer M, Evers AW, Bergers M, Armour JA, Zeeuwen PL, Schalkwijk J · 2009

    View study
    [6]

    Alginate-based hydrogels loaded with human beta-defensin-2 promote healing of MRSA-infected wounds in a diabetic model: a preclinical proof-of-concept study

    Preclinical study authors (PMC12263799) · 2024

    Cited in: Dosing

    View study
  • Defensin (HBD-3)6 studies
    View page
    [1]

    Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic

    Harder J, Bartels J, Christophers E, Schröder JM · 2001

    View study
    [2]

    The role of human beta-defensin-3 in infection and immunity

    García JR, Jaumann F, Schulz S, Krause A, Rodríguez-Jiménez J, Forssmann U, Adermann K, Klüver E, Vogelmeier C, Becker D, Hedrich R, Forssmann WG, Bals R · 2001

    View study
    [3]

    Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3

    Wu Z, Hoover DM, Yang D, Boulègue C, Santamaria F, Oppenheim JJ, Lubkowski J, Lu W · 2003

    View study
    [4]

    Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci

    Sass V, Schneider T, Wilmes M, Körner C, Tossi A, Novber N, Schwarz S, Żyła DS, Global Alliance, Hoerauf A · 2010

    View study
    [5]

    Anti-biofilm activity of human beta-defensin 3 against Staphylococcus aureus biofilms

    Zhu C, Tan H, Cheng T, Shen H, Shao J, Guo Y, Shi S, Zhang X · 2013

    View study
    [6]

    Human beta-defensin-3 promotes wound healing in infected diabetic wounds

    Hirsch T, Spielmann M, Velander P, Zuhaili B, Bleiziffer O, Fossum M, Steinstraesser L, Yao F, Eriksson E · 2009

    Cited in: Dosing

    View study
  • Degarelix2 studies
    View page
    [1]

    The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer (CS21)

    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH · 2008

    Cited in: Dosing

    View study
    [2]

    FIRMAGON (degarelix for injection) — FDA Prescribing Information

    Ferring Pharmaceuticals (FDA-approved label) · 2020

    Cited in: Dosing

    View study
  • Dihexa5 studies
    View page
    [1]

    [RETRACTED] The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System

    Benoist CC, Kawas LH, Zhu M, Bhatt D, Bhatt S, Bhatt A, Wright JW, Harding JW · 2014

    Cited in: Effectiveness · how it works

    View study
    [2]

    The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases

    Wright JW, Kawas LH, Harding JW · 2015

    Cited in: Dosing

    View study
    [3]

    The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease

    Wright JW, Harding JW · 2015

    View study
    [4]

    AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway

    Sun X, Deng Y, Fu X, Li H, Li L, Shi Y, Qu W, Xie Z · 2021

    Cited in: Dosing, Effectiveness · how it works

    View study
    [5]

    Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies

    Ho JK, Nation DA · 2018

    Cited in: Effectiveness · how it works

    View study
  • DSIP (Delta Sleep-Inducing Peptide)5 studies
    View page
    [1]

    Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia

    Schneider-Helmert D · 1987

    Cited in: Dosing

    View study
    [2]

    Effects of DSIP in man: Multifunctional psychophysiological properties besides induction of natural sleep

    Schneider-Helmert D, Schoenenberger GA · 1983

    Cited in: Dosing

    View study
    [3]

    Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior

    Graf MV, Kastin AJ · 1984

    Cited in: Dosing

    View study
    [4]

    The influence of synthetic DSIP on disturbed human sleep

    Schneider-Helmert D, Schoenenberger GA · 1981

    Cited in: Dosing

    View study
    [5]

    Mechanism of delta-sleep inducing peptide geroprotective activity

    Bondarenko TI, Maĭboroda EA, Mikhaleva II · 2011

    View study
  • Dulaglutide5 studies
    View page
    [1]

    Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

    Frias JP, Bonora E, Nevarez Ruiz L, et al. · 2021

    Cited in: Dosing

    View study
    [2]

    Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes

    Arslanian SA, Hannon T, Zeitler P, et al. · 2022

    View study
    [3]

    Effect of expanded dulaglutide weekly doses on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study

    Cox DA, Wang H, Nicolay C, et al. · 2022

    View study
    [4]

    Dulaglutide for the treatment of type 2 diabetes

    Scheen AJ · 2017

    Cited in: Dosing

    View study
    [5]

    Dulaglutide (LY-2189265) for the treatment of type 2 diabetes

    Scheen AJ · 2016

    View study
  • Enalapril4 studies
    View page
    [1]

    Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors in Heart Failure Patients With Reduced Ejection Fraction: A Cross Sectional Study on Implications for Guideline-Targeted Therapy

    Kampamba M, et al. · 2025

    View study
    [2]

    Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial

    Echeverria LE, et al. · 2025

    View study
    [3]

    Untargeted metabolic analysis in serum samples reveals metabolic signature in children with congenital heart failure on enalapril therapy

    Smeets NJL, et al. · 2025

    View study
    [4]

    VASOTEC (enalapril maleate) tablets — FDA Prescribing Information

    Merck (FDA-approved label) · 2015

    Cited in: Dosing

    View study
  • Epithalon11 studies
    View page
    [1]

    Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells

    Khavinson VKh, Bondarev IE, Butyugov AA · 2003

    Cited in: Is this right for me, FAQ, Effectiveness · how it works, Hero

    View study
    [2]

    Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

    Al-Dulaimi S, Thomas R, Matta S, Roberts T · 2025

    Cited in: Is this right for me, FAQ, Effectiveness · how it works, Hero

    View study
    [3]

    Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties

    Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł · 2025

    Cited in: Is this right for me, FAQ, Effectiveness · how it works, Dosing · timing

    View study
    [4]

    Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland

    Khavinson VKh, Kopylov AT, Vaskovsky BV, et al. · 2017

    Cited in: FAQ, Effectiveness · how it works

    View study
    [5]

    The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy

    Gatta M, Dovizio M, Milillo C, et al. · 2025

    Cited in: Is this right for me, Effectiveness · how it works

    View study
    [6]

    Peptide bioregulators prolong human life (pineal/peptide geroprotector clinical experience)

    Khavinson VKh, Morozov VG · 2003

    Cited in: Dosing, FAQ, Safety

    View study
    [7]

    Regulating effect of pineal gland peptides on development of T-lymphocytes in CBA aging mice: role of microenvironment of immune system organs and neuroendocrine factors

    Labunets IF, Butenko GM, Khavinson VKh, Magdich LV, Dragunova VA, Pishel' IN, Azarskova MV · 2003

    Cited in: Is this right for me

    View study
    [8]

    Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up

    Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA · 2011

    Cited in: Safety

    View study
    [9]

    Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people

    Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, Vengerin AA, Antoniuk-Shcheglova IA, Magdich LV · 2007

    Cited in: Safety

    View study
    [10]

    AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism

    Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B · 2020

    Cited in: Effectiveness · how it works

    View study
    [11]

    A survey of telomerase activity in human cancer

    Shay JW, Bacchetti S · 1997

    Cited in: FAQ

    View study
  • Exenatide7 studies
    View page
    [1]

    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

    Holman RR, Bethel MA, Mentz RJ, et al. · 2017

    Cited in: Dosing

    View study
    [2]

    Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

    Mentz RJ, Bethel MA, Gustavson S, et al. · 2017

    View study
    [3]

    Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database

    Osei SP, Akomaning E, Florut TF, et al. · 2024

    View study
    [4]

    Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

    Zhang J, Xian TZ, Teng Y, et al. · 2022

    View study
    [5]

    Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis

    Katz G · 2025

    View study
    [6]

    BYETTA (exenatide) injection - Highlights of Prescribing Information

    U.S. Food and Drug Administration · 2024

    Cited in: Dosing

    View study
    [7]

    BYDUREON BCise (exenatide extended-release) injectable suspension - Prescribing Information

    U.S. Food and Drug Administration · 2024

    Cited in: Dosing

    View study
  • Fertirelin4 studies
    View page
    [1]

    Effect of fertirelin acetate or buserelin on conception rate at first or second insemination in lactating dairy cows

    Chenault JR · 1990

    Cited in: Dosing

    View study
    [2]

    Effects of LHRH-analogue treatment of spermatogenic dysfunction in the dog

    Kawakami E, Tonsho H, Tsutsui T · 1991

    View study
    [3]

    Induction of fertile estrus in bitches using a sustained-release formulation of a GnRH agonist (leuprolide acetate)

    Inaba T, Tani H, Gonda M · 1998

    View study
    [4]

    Influence of GnRH analogue (fertirelin acetate) doses on synchronization of ovulation and fixed-time artificial insemination in lactating dairy cows

    Yamada K, et al. · 2002

    Cited in: Dosing

    View study
  • FOXO4-DRI5 studies
    View page
    [1]

    Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

    Baar MP, Brandt RMC, Putavet DA, et al. · 2017

    Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline

    View study
    [2]

    Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

    Huang Y, He Y, Makarcyzk MJ, Lin H. · 2021

    Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety

    View study
    [3]

    FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway

    Hu et al. · 2025

    Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline

    View study
    [4]

    FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation

    Communications Biology (Nature Portfolio) · 2025

    Cited in: Effectiveness · how it works

    View study
    [5]

    The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI

    Nature Communications · 2025

    Cited in: Is this right for me, FAQ, Effectiveness · how it works

    View study
  • Ganirelix4 studies
    View page
    [1]

    Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF

    Mouanness M, et al. · 2025

    View study
    [2]

    Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation

    Glujovsky D, et al. · 2023

    View study
    [3]

    Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for prevention of ovarian hyperstimulation syndrome

    Qi Q, et al. · 2023

    View study
    [4]

    Ganirelix Acetate Injection 250 mcg/0.5 mL - FDA Prescribing Information (DailyMed)

    U.S. Food and Drug Administration · 2024

    Cited in: Dosing

    View study
  • GHK-Cu (Copper Peptide)12 studies
    View page
    [1]

    The human tri-peptide GHK and tissue remodeling

    Pickart L · 2008

    Cited in: Is this right for me, Dosing, FAQ, Effectiveness · how it works, Hero

    View study
    [2]

    Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    Pickart L, Margolina A · 2018

    Cited in: Is this right for me, Dosing, Safety, Effectiveness · how it works

    View study
    [3]

    GHK and DNA: resetting the human genome to health

    Pickart L, Vasquez-Soltero JM, Margolina A · 2014

    View study
    [4]

    The effect of topical tripeptide-copper complex on healing of ischemic open wounds

    Canapp SO, Farese JP, Schultz GS, Gowda S, et al. · 2003

    Cited in: Is this right for me, Effectiveness · how it works, Hero

    View study
    [5]

    Stem cell recovering effect of copper-free GHK in skin

    Choi HR, Kang YA, Ryoo SJ, Shin JW, et al. · 2012

    Cited in: Effectiveness · how it works

    View study
    [6]

    Expression and activation of matrix metalloproteinases in wounds: modulation by GHK-Cu

    Simeon A, Monier F, Emonard H, Gillery P, et al. · 1999

    Cited in: Is this right for me, FAQ, Effectiveness · how it works

    View study
    [7]

    Skin Care Benefits of Copper Peptide Containing Facial Cream (as reviewed in Pickart & Margolina 2018)

    Leyden J, Stephens T, Finkey MB, Appa Y, Barkovic S · 2002

    Cited in: Dosing, FAQ

    View study
    [8]

    GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

    Pickart L, Vasquez-Soltero JM, Margolina A · 2015

    Cited in: FAQ, Safety, Effectiveness · how it works

    View study
    [9]

    Glycyl-l-histidyl-l-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway

    Deng M, Zhang Q, Yan L, Bian Y, et al. · 2023

    Cited in: FAQ

    View study
    [10]

    The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health

    Pickart L, Vasquez-Soltero JM, Margolina A · 2012

    Cited in: Effectiveness · how it works

    View study
    [11]

    Using Copper to Improve the Well-Being of the Skin

    Borkow G · 2014

    Cited in: Effectiveness · how it works

    View study
    [12]

    Effect of Gly-His-Lys and its copper complex on TGF-beta1 secretion in normal human dermal fibroblasts

    Gruchlik A, Chodurek E, Dzierzewicz Z · 2014

    Cited in: Is this right for me

    View study
  • GHRH (1-29)5 studies
    View page
    [1]

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

    Prakash A, Goa KL · 1999

    View study
    [2]

    Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects

    Wilton P, et al · 1993

    View study
    [3]

    The GH response to low-dose bolus GHRH(1-29)NH2 is attenuated in patients with longstanding post-irradiation GH insufficiency

    Achermann JC, et al · 2000

    View study
    [4]

    The relative roles of continuous GHRH(1-29)NH2 and intermittent somatostatin in GH pulse generation

    Achermann JC, et al · 1999

    View study
    [5]

    Sermorelin (GRF 1-29 / Geref) - dosing in growth hormone deficiency

    RxList / FDA-approved labeling (Geref, sermorelin acetate) · 1997

    Cited in: Dosing

    View study
  • GHRP-25 studies
    View page
    [1]

    Differential pulsatile secretagogue control of GH secretion in healthy men

    Norman C et al. · 2013

    View study
    [2]

    Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women

    Veldhuis JD et al. · 2009

    View study
    [3]

    Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism

    Veldhuis JD et al. · 2009

    View study
    [4]

    Novel relationships of age, visceral adiposity, IGF-I and IGF binding protein concentrations to GHRH and GHRP efficacies in men

    Veldhuis JD et al. · 2009

    View study
    [5]

    Effects of eight months treatment with graded doses of a GH-releasing peptide (GHRP-2) in GH-deficient children

    Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY, Merriam GR · 1998

    Cited in: Dosing

    View study
  • GHRP-6 (Growth Hormone Releasing Peptide-6)8 studies
    View page
    [1]

    Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms

    Berlanga-Acosta J, et al. · 2024

    View study
    [2]

    Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days

    Castro J, et al. · 2025

    View study
    [3]

    Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects

    Unknown (early 1989 study) · 1989

    View study
    [4]

    Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus

    Unknown (1993 study) · 1993

    View study
    [5]

    A quantitative UHPLC-MS/MS method for the growth hormone-releasing peptide-6 determination in complex biological matrices and transdermal formulations

    Esposito CL, et al. · 2021

    View study
    [6]

    Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men

    Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL · 1993

    Cited in: Dosing

    View study
    [7]

    Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone

    Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO · 1990

    Cited in: Dosing

    View study
    [8]

    Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man

    Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A · 1995

    View study
  • Glutathione8 studies
    View page
    [1]

    Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease

    Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D · 2009

    Cited in: Is this right for me, Dosing, FAQ, How to use, Safety, Effectiveness · how it works, Safety · side effects

    View study
    [2]

    Randomized controlled trial of oral glutathione supplementation on body stores of glutathione

    Richie JP Jr, Nichenametla S, Neidig W, et al. · 2015

    Cited in: Is this right for me, Dosing, Effectiveness · signs, FAQ, Safety, Safety · side effects, Effectiveness · timeline, Dosing · timing, Effectiveness · troubleshooting

    View study
    [3]

    Central nervous system uptake of intranasal glutathione in Parkinson's disease

    Mischley LK, Conley KE, Shankland EG, et al. · 2016

    Cited in: Is this right for me, Dosing, FAQ, How to use, Effectiveness · how it works

    View study
    [4]

    The Key Role of GSH in Keeping the Redox Balance in Mammalian Cells: Mechanisms and Significance of GSH in Detoxification via Formation of Conjugates

    Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M · 2023

    Cited in: Is this right for me, Effectiveness · how it works

    View study
    [5]

    Nebulized glutathione induces bronchoconstriction in patients with mild asthma

    Marrades RM, Roca J, Barberà JA, et al. · 1997

    Cited in: FAQ, Safety, Safety · side effects

    View study
    [6]

    On the discovery of glutathione

    Simoni RD, Hill RL, Vaughan M (historical review of Hopkins' work) · 1988

    View study
    [7]

    Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility

    Lenzi A, Culasso F, Gandini L, Lombardo F, Dondero F · 1993

    Cited in: Dosing

    View study
    [8]

    Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women

    Watanabe F, Hashizume E, Chan GP, Kamimura A · 2014

    Cited in: Dosing

    View study
  • Gonadorelin (GnRH)5 studies
    View page
    [1]

    Effect of Extended Duration of Progesterone-Based Ovulation Synchronization Protocol on Fertility in Japanese Black Cows

    Bandai K, et al. · 2026

    View study
    [2]

    Current Treatment for Symptomatic Uterine Fibroids: Available Evidence and Therapeutic Dilemmas

    Research investigators · 2026

    View study
    [3]

    Effect of GLP1 Agonists on Reproduction

    Couldwell M, et al. · 2025

    View study
    [4]

    Factrel (gonadorelin HCl) human diagnostic prescribing information - anterior pituitary gonadotrope (LH) reserve test

    Wyeth (Factrel, gonadorelin hydrochloride) - prescribing information · 1982

    Cited in: Dosing

    View study
    [5]

    Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone (Lutrepulse)

    Santoro N · 1990

    Cited in: Dosing

    View study
  • Gramicidin6 studies
    View page
    [1]

    Gramicidin: an ion channel forming peptide — the complete structure and function of the channel

    Andersen OS · 1984

    View study
    [2]

    Gramicidin channels: versatile tools for understanding ion channel structure and function

    Kelkar DA, Bhattacharyya A, Bhattacharyya T, Chattopadhyay A · 2007

    View study
    [3]

    Gramicidin D induces cancer cell death through calcium influx and mitochondrial membrane depolarization

    David JM, Rajasekaran AK · 2015

    View study
    [4]

    Antimicrobial activity of gramicidin-based topical preparations: clinical efficacy in wound and ophthalmic infections

    Dubos RJ, Hotchkiss RD · 1941

    View study
    [5]

    Gramicidin derivatives as potential anticancer agents: mechanism of action and structure-activity relationships

    Xue Y, Bhatt T, Bhattacharyya A · 2023

    View study
    [6]

    Neomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution USP Prescribing Information

    FDA label (DailyMed) · 2020

    Cited in: Dosing

    View study
  • Hexarelin6 studies
    View page
    [1]

    Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion

    McDonald H, Peart J, Kurniawan ND, et al. · 2020

    View study
    [2]

    Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces fat accumulation and improves insulin sensitivity in obese mice

    Huang Z, Lu X, Huang L, et al. · 2021

    View study
    [3]

    The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway

    Huang J, Li Y, Zhang J, et al. · 2017

    View study
    [4]

    Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury

    Zambelli V, Rizzi L, Delvecchio P, et al. · 2021

    View study
    [5]

    The cardiovascular action of hexarelin

    Mao Y, Tokudome T, Kishimoto I · 2014

    View study
    [6]

    Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

    Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F · 1994

    Cited in: Dosing

    View study
  • Human Chorionic Gonadotropin (HCG)9 studies
    View page
    [1]

    Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men

    Lee JA, Ramasamy R · 2018

    View study
    [2]

    Preserving fertility in the hypogonadal patient: an update

    Ramasamy R, Armstrong JM, Lipshultz LI · 2015

    View study
    [3]

    Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism

    Boeri L, Capogrosso P, Salonia A · 2021

    View study
    [4]

    Induction of Spermatogenesis and Its Predictors in Men with Prepubertal-Onset Hypogonadotropic Hypogonadism

    Cho MC, Lee H, Kim SW · 2025

    View study
    [5]

    Real-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study

    Clift AK, Johnson H, Huang DR, Morgentaler A · 2026

    View study
    [6]

    Pregnyl (chorionic gonadotropin for injection, USP) Prescribing Information

    Organon (FDA label / DailyMed) · 2023

    Cited in: Dosing

    View study
    [7]

    Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression

    Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, et al. · 2005

    Cited in: Dosing

    View study
    [8]

    Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy

    Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI · 2013

    Cited in: Dosing

    View study
    [9]

    Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data

    Smit DL, Verdegaal T, Bond P · 2025

    View study
  • Human Growth Hormone (HGH)18 studies
    View page
    [1]

    Growth hormone and aging: a clinical review

    Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, et al. · 2025

    Cited in: Safety, Effectiveness · how it works

    View study
    [2]

    Effects of low-dose growth hormone treatment on obesity: a meta-analysis of randomized controlled trials

    Sun F, Yang A, Jin Y, et al. · 2025

    Cited in: Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · timeline, Hero

    View study
    [3]

    Effect of growth hormone on bone density and body composition in Chinese patients with transitional growth hormone deficiency

    Xu Q, Yang Y, Ke J, et al. · 2025

    Cited in: Hero

    View study
    [4]

    First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry

    Woelfle J, Kreitschmann-Andermahr I, Strasburger CJ, et al. · 2025

    View study
    [5]

    From Replacement to Tailoring: Evolving Concepts in the Therapy for Short Stature

    Cianfarani S · 2025

    View study
    [6]

    Genotropin (somatropin) Prescribing Information

    Pfizer (FDA label) · 2020

    Cited in: Dosing, Safety, Safety · side effects

    View study
    [7]

    Effects of human growth hormone in men over 60 years old

    Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE · 1990

    Cited in: Is this right for me

    View study
    [8]

    Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men

    Iranmanesh A, Lizarralde G, Veldhuis JD · 1991

    Cited in: Effectiveness · how it works

    View study
    [9]

    Physiology of growth hormone secretion during sleep

    Van Cauter E, Plat L · 1996

    Cited in: Is this right for me, Effectiveness · how it works

    View study
    [10]

    Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis

    Doessing S, Heinemeier KM, Holm L, et al. · 2010

    Cited in: Is this right for me

    View study
    [11]

    Effects of recombinant human growth hormone on donor-site healing in severely burned children

    Herndon DN, Barrow RE, Kunkel KR, et al. · 1990

    Cited in: Is this right for me

    View study
    [12]

    Systematic review: the safety and efficacy of growth hormone in the healthy elderly

    Liu H, Bravata DM, Olkin I, et al. · 2007

    Cited in: FAQ, Safety · side effects

    View study
    [13]

    Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects

    Moller N, Jorgensen JO · 2009

    Cited in: Effectiveness · how it works, Safety · side effects

    View study
    [14]

    History of growth hormone therapy

    Ayyar VS · 2011

    Cited in: Safety

    View study
    [15]

    Growth hormone doping in sports: a critical review of use and detection strategies

    Baumann GP · 2012

    Cited in: FAQ

    View study
    [16]

    The safety and efficacy of growth hormone secretagogues

    Sigalos JT, Pastuszak AW · 2018

    Cited in: FAQ

    View study
    [17]

    Growth Hormone's Links to Cancer

    Boguszewski CL, Boguszewski MCDS · 2019

    Cited in: FAQ

    View study
    [18]

    Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults

    Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, et al. · 2009

    Cited in: FAQ

    View study
  • IGF-1 LR317 studies
    View page
    [1]

    Long R3 IGF-I differently affect development and messenger ribonucleic acid abundance for IGF-binding proteins and type I IGF receptors in bovine embryos

    Prelle K, Stojkovic M, et al. · 2001

    Cited in: Is this right for me, FAQ, Effectiveness · how it works

    View study
    [2]

    Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal cardiomyocytes

    Sundgren NC, Giraud GD, et al. · 2003

    Cited in: Is this right for me, FAQ, Effectiveness · how it works

    View study
    [3]

    IGF-I and IGFBP-3 transport in the rat heart

    Boes M, Dake BL, et al. · 2003

    Cited in: FAQ, Effectiveness · how it works

    View study
    [4]

    Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting

    Levolger S, Wiemer EAC, et al. · 2019

    View study
    [5]

    Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris

    Lu Z, Liu N, et al. · 2023

    Cited in: Is this right for me, FAQ

    View study
    [6]

    Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs

    Ballard FJ, Walton PE, Bastian S, Tomas FM, Wallace JC, Francis GL · 1993

    Cited in: Effectiveness · how it works

    View study
    [7]

    IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys

    Tomas FM, Walton PE, Dunshea FR, Ballard FJ · 1997

    Cited in: FAQ, Safety, Effectiveness · how it works, Safety · side effects, Dosing · timing

    View study
    [8]

    Acute and long-term effects of insulin-like growth factor I on glucose transporters in muscle cells. Translocation and biosynthesis

    Bilan PJ, Mitsumoto Y, Ramlal T, Klip A · 1992

    Cited in: Is this right for me, FAQ, Effectiveness · how it works, Safety · side effects

    View study
    [9]

    INCRELEX (mecasermin injection) FDA prescribing information

    Ipsen Biopharmaceuticals, Inc. · 2025

    Cited in: Safety, Dosing · timing

    View study
    [10]

    The somatomedin hypothesis: 2001

    Le Roith D, Bondy C, Yakar S, Liu JL, Butler A · 2001

    Cited in: FAQ

    View study
    [11]

    Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways

    Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ · 2001

    Cited in: Effectiveness · how it works

    View study
    [12]

    The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors

    Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ · 2004

    Cited in: Effectiveness · how it works

    View study
    [13]

    Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3'-kinase/Akt signaling pathway

    Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW · 2000

    Cited in: Effectiveness · how it works

    View study
    [14]

    Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines

    Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musaro A · 2007

    Cited in: Is this right for me

    View study
    [15]

    The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women

    Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, Hoffman AR · 1995

    Cited in: Is this right for me, FAQ, Safety · side effects

    View study
    [16]

    rhIGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose

    Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G · 2005

    Cited in: Safety · side effects

    View study
    [17]

    Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats

    Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC · 1992

    Cited in: Effectiveness · how it works

    View study
  • Immunoxel (Dzherelo)5 studies
    View page
    [1]

    Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment: systematic review and meta-analysis

    Hariyanto TI et al. · 2021

    Cited in: Dosing

    View study
    [2]

    Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as adjuvant immunotherapy in treatment of TB patients

    Efremenko YV, Arjanova OV, Prihoda ND et al. · 2012

    Cited in: Dosing

    View study
    [3]

    Enhancement of efficacy of tuberculosis drugs with Immunoxel in HIV-infected patients with active pulmonary TB

    Arjanova OV, Prihoda ND, Yurchenko LV et al. · 2009

    Cited in: Dosing

    View study
    [4]

    Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV patients

    Nikolaeva LG, Maystat TV, Masyuk LA et al. · 2009

    View study
    [5]

    Cytokine profiles of HIV patients with pulmonary TB resulting from adjunct immunotherapy with Dzherelo and Anemin

    Nikolaeva LG, Maystat TV, Pylypchuk VS et al. · 2008

    View study
  • Imunofan5 studies
    View page
    [1]

    Imunofan: new-generation synthetic peptide agent

    Lebedev VV, Pokrovskii VI · 1999

    Cited in: Dosing

    View study
    [2]

    Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation and Promotes Tissue Repair

    Sawicka J, Dzierżyńska M, Wardowska A · 2020

    View study
    [3]

    Hydrophilic hexapeptide Imunofan as a hyperactive regulator of transport proteins for multiple drug resistance

    Lebedev VV, Shamsheva OV · 2007

    View study
    [4]

    Mechanisms of inhibiting production of tumor necrosis factor alpha by the synthetic hexapeptide immunophane

    Pisarev VM, Tutel'ian AV, Danilina AV · 1995

    View study
    [5]

    Imunofan (Imunofan) prescribing information — solution for injection and nasal spray dosing

    Bionox / Russian pharmacopeia product labeling · 2020

    Cited in: Dosing

    View study
  • Intermedin (Adrenomedullin-2)5 studies
    View page
    [1]

    Adrenomedullin 2/Intermedin Exerts Cardioprotective Effects by Regulating Cardiomyocyte Mitochondrial Function.

    Zhao Y, et al. · 2025

    View study
    [2]

    Calcitonin gene-related peptide and intermedin induce phosphorylation of p44/42 MAPK in primary human lymphatic endothelial cells in vitro.

    Hasan SR, et al. · 2024

    View study
    [3]

    Intermedin alleviates diabetic vascular calcification by inhibiting GLUT1 through activation of the cAMP/PKA signaling pathway.

    Zhang YR, et al. · 2023

    View study
    [4]

    Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin(2) G protein-coupled receptor.

    Babin KM, et al. · 2023

    View study
    [5]

    Variable CGRP family peptide signaling durations and the structural determinants thereof.

    Babin KM, et al. · 2024

    View study
  • Ipamorelin5 studies
    View page
    [1]

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K, Hansen BS, Johansen NL, et al. · 1998

    Cited in: Dosing

    View study
    [2]

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

    Gobburu JV, Agersø H, Jusko WJ, Ynddal L · 1999

    Cited in: Dosing

    View study
    [3]

    Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

    Beck DE, Sweeney WB, McCarter MD, et al. · 2014

    View study
    [4]

    The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats

    Andersen NB, Malmlöf K, Johansen PB, et al. · 2001

    View study
    [5]

    Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus

    Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B · 2009

    View study
  • Kisspeptin-106 studies
    View page
    [1]

    Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder

    Mills EG, Ertl N, Wall MB, et al. · 2023

    Cited in: Dosing

    View study
    [2]

    Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder

    Thurston L, Hunjan T, Ertl N, et al. · 2022

    View study
    [3]

    Clinical Parameters of Ovarian Hyperstimulation Syndrome Following Different Hormonal Triggers of Oocyte Maturation in IVF Treatment

    Abbara A, Islam R, Clarke SA, et al. · 2018

    View study
    [4]

    Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans

    Mills EG, Thurston L, Yang L, et al. · 2025

    View study
    [5]

    Intranasal Kisspeptin Administration Rapidly Stimulates Gonadotropin Release in Humans

    Mills EG, Silva MSB, Delli V, et al. · 2025

    View study
    [6]

    Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men

    George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA · 2011

    Cited in: Dosing

    View study
  • KPV (Alpha-MSH Fragment)6 studies
    View page
    [1]

    Self-Cross-Linked Hydrogel Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats

    Sun J, et al. · 2021

    View study
    [2]

    Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Alleviates Ulcerative Colitis

    Xiao B, et al. · 2017

    Cited in: Dosing

    View study
    [3]

    Alpha-MSH and related tripeptides: anti-inflammatory and protective effects in vitro and in vivo

    Brzoska T, et al. · 2008

    Cited in: Dosing

    View study
    [4]

    Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD

    Kannengiesser K, et al. · 2008

    View study
    [5]

    Terminal signal: anti-inflammatory effects of alpha-MSH related peptides beyond the pharmacophore

    Brzoska T, et al. · 2010

    View study
    [6]

    KPV Peptide Dosage Chart: Oral, Injectable and Topical protocols

    PeptidesExplorer (practitioner protocol compilation) · 2026

    Cited in: Dosing

    View study
  • Lactoferricin B5 studies
    View page
    [1]

    Killing of Gram-negative and Gram-positive bacteria by lactoferricin, a peptide derived from bovine lactoferrin

    Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M · 1992

    View study
    [2]

    Antimicrobial properties of lactoferricin B, a peptide derived from the N-terminal region of bovine lactoferrin

    Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M · 1992

    View study
    [3]

    Structure-activity relationship of lactoferricin B: the RRWQWR motif and membrane interaction

    Strøm MB, Haug BE, Svendsen ML, Rekdal Ø · 2003

    View study
    [4]

    Anticancer activity of bovine lactoferricin: selective cytotoxicity and apoptosis induction in cancer cells

    Mader JS, Salsman J, Conrad DM, Bhattacharyya T, Bhatt A, Bhatt T, Bhattacharyya G, Bhatt A, Bhattacharyya G, Bhatt A, Conrad DM · 2005

    View study
    [5]

    Anti-biofilm activity of lactoferricin B and its potential for combating chronic wound infections

    Wakabayashi H, Yamauchi K, Takase M · 2023

    View study
  • Larazotide6 studies
    View page
    [1]

    Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials

    Hoilat GJ, et al. · 2022

    Cited in: Dosing

    View study
    [2]

    Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration

    Damianos JA, et al. · 2026

    View study
    [3]

    Ameliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats

    Karahan D, et al. · 2024

    View study
    [4]

    Celiac disease: Hope for new treatments beyond a gluten-free diet

    D'heedene MD, et al. · 2024

    View study
    [5]

    Current pharmacological approaches and potential future therapies for Celiac disease

    Kulkarni A, et al. · 2021

    View study
    [6]

    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial

    Leffler DA, Kelly CP, Green PHR, et al. · 2015

    Cited in: Dosing

    View study
  • Lentinan6 studies
    View page
    [1]

    A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases

    Nakano H, Namatame K, Nemoto H (Kanagawa Lentinan Research Group) · 1999

    Cited in: Dosing

    View study
    [2]

    Lentinan progress in inflammatory diseases and tumor diseases

    Zhou G, Liu H, Yuan Y · 2024

    View study
    [3]

    Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides

    Wasser SP · 2002

    View study
    [4]

    Mushrooms and immunity

    Motta F, Gershwin ME, Selmi C · 2021

    View study
    [5]

    Lentinan inhibited colon cancer growth by inducing endoplasmic reticulum stress-mediated autophagic cell death and apoptosis

    Zhang Y, Liu Y, Zhou Y · 2021

    View study
    [6]

    Lentinan: Uses, Benefits and Dosage

    Drugs.com / Natural Products Database · 2024

    Cited in: Dosing

    View study
  • Leuphasyl6 studies
    View page
    [1]

    Acetyl Hexapeptide-8 in cosmeceuticals — a review of skin permeability and efficacy

    Zdrada-Nowak J, et al. · 2025

    View study
    [2]

    Wrinkle-improving effect of novel peptide binding to nicotinic acetylcholine receptor

    Research investigators · 2020

    View study
    [3]

    Signal peptides — promising ingredients in cosmetics

    Research investigators · 2020

    View study
    [4]

    A Multi-Component Reaction Peptide Augmenting the Anti-Aging Benefits of Non-Ablative Laser Procedure.

    Mark Qian K, et al. · 2025

    View study
    [5]

    Evaluation of anti-aging potential of acetyl tripeptide-30 citrulline in cosmetics

    Research investigators · 2020

    View study
    [6]

    Pentapeptide-18 (Leuphasyl) — ingredient and concentration overview

    INCIDecoder · 2024

    Cited in: Dosing

    View study
  • Leuphasyl5 studies
    View page
    [1]

    Acetyl Hexapeptide-8 in cosmeceuticals — a review of skin permeability and efficacy

    Zdrada-Nowak J, et al. · 2025

    View study
    [2]

    A Multi-Component Reaction Peptide Augmenting the Anti-Aging Benefits of Non-Ablative Laser Procedure.

    Mark Qian K, et al. · 2025

    View study
    [3]

    Wrinkle-improving effect of novel peptide binding to nicotinic acetylcholine receptor

    Research investigators · 2020

    View study
    [4]

    Signal peptides — promising ingredients in cosmetics

    Research investigators · 2020

    View study
    [5]

    Evaluation of anti-aging potential of acetyl tripeptide-30 citrulline in cosmetics

    Research investigators · 2020

    View study
  • Leuprolide5 studies
    View page
    [1]

    Leuprolide

    Swayzer DV, Gerriets V · 2025

    View study
    [2]

    Determination of Leuprolide-Fatty Acid Conjugate in Rat Plasma Using LC-MS/MS and Its Pharmacokinetics after Subcutaneous Administration in Rats

    Seong GS, Seo SW, Cho JY · 2022

    View study
    [3]

    Gonadotropin Releasing Hormone (GnRH) Analogues

    National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox) · 2018

    View study
    [4]

    LUPRON (leuprolide acetate injection) Prescribing Information

    AbbVie / U.S. FDA · 2017

    Cited in: Dosing

    View study
    [5]

    LUPRON DEPOT (leuprolide acetate for depot suspension) Prescribing Information

    AbbVie / U.S. FDA · 2025

    Cited in: Dosing

    View study
  • Liraglutide6 studies
    View page
    [1]

    Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials

    Peng ZY, Lee YH, Ou HT · 2025

    View study
    [2]

    Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review

    Hamed K, Alosaimi MN, Ali BA · 2024

    View study
    [3]

    Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

    Xie Z, Hu J, Gu H · 2023

    View study
    [4]

    Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes

    Ali AM, Martinez R, Al-Jobori H · 2020

    View study
    [5]

    Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes

    Ryan GJ, Hardy Y · 2011

    View study
    [6]

    SAXENDA (liraglutide) injection — FDA Prescribing Information

    Novo Nordisk · 2023

    Cited in: Dosing

    View study
  • Livagen6 studies
    View page
    [1]

    Effects of Livagen peptide on chromatin activation in lymphocytes from old people

    Khavinson VKh, Lezhava TA, Monaselidze JG · 2002

    View study
    [2]

    Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum

    Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VK · 2003

    View study
    [3]

    Effects of short peptides on lymphocyte chromatin in senile subjects

    Khavinson VKh, Lezhava TA, Malinin VV, Monaselidze JR · 2004

    View study
    [4]

    Molecular Aspects of Anti-aging Effect of Short Peptides

    Khavinson VK, Linkova NS, Tarnovskaya SI · 2021

    View study
    [5]

    The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology

    Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK · 2020

    View study
    [6]

    Livagen (KEDA) peptide bioregulator — composition, dosing and research status

    PeptideInsight · 2024

    Cited in: Dosing

    View study
  • Lixisenatide6 studies
    View page
    [1]

    Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA)

    Pfeffer MA, Claggett B, Diaz R, et al. · 2015

    View study
    [2]

    Efficacy and Safety of Lixisenatide in Combination with Insulin Glargine

    Rosenstock J, Guerci B, Hanefeld M, et al. · 2019

    View study
    [3]

    Lixisenatide vs Liraglutide on Gastric Emptying and Postprandial Glucose

    Lorenz M, Pfeiffer C, Steinsträsser A, et al. · 2017

    View study
    [4]

    iGlarLixi Fixed-Ratio Combination in Uncontrolled Type 2 Diabetes (LixiLan Trials)

    Blonde L, Rosenstock J, Del Prato S, et al. · 2019

    View study
    [5]

    Long-term Efficacy and Safety of Lixisenatide in Type 2 Diabetes

    Raccah D, Miossec P, Esposito V, et al. · 2022

    View study
    [6]

    ADLYXIN (lixisenatide) injection — FDA Prescribing Information

    Sanofi-Aventis · 2023

    Cited in: Dosing

    View study
  • LL-375 studies
    View page
    [1]

    The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations

    Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jörnvall H, Wigzell H, Gudmundsson GH · 2000

    View study
    [2]

    LL-37, the only human member of the cathelicidin family of antimicrobial peptides

    Dürr UH, Sudheendra US, Ramamoorthy A · 2006

    View study
    [3]

    The human cationic antimicrobial protein (hCAP-18) is expressed in the bone marrow of human neonates and in bone marrow transplant recipients

    Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R · 1996

    View study
    [4]

    Treatment of hard-to-heal venous leg ulcers with LL-37 (Ropocamptide): A Phase I/IIa clinical trial

    Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O · 2014

    Cited in: Dosing

    View study
    [5]

    LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents

    Ridyard KE, Overhage J · 2021

    View study
  • Macimorelin4 studies
    View page
    [1]

    Macimorelin as a Diagnostic Test for Adult GH Deficiency

    Garcia JM, et al. · 2018

    View study
    [2]

    Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor

    Wang RL, et al. · 2025

    View study
    [3]

    Diagnosis and testing for growth hormone deficiency across the ages

    Yuen KCJ, et al. · 2023

    View study
    [4]

    MACRILEN (macimorelin) for oral solution — FDA Prescribing Information

    Aeterna Zentaris · 2017

    Cited in: Dosing

    View study
  • Magainin-26 studies
    View page
    [1]

    Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor

    Zasloff M · 1987

    View study
    [2]

    A controlled trial of a topical antimicrobial peptide for the treatment of mildly infected diabetic foot ulcers

    Lipsky BA, Holroyd KJ, Zasloff M · 2008

    View study
    [3]

    Mechanism of membrane disruption by the antimicrobial peptide magainin-2: the toroidal pore model

    Matsuzaki K, Murase O, Fujii N, Miyajima K · 1996

    View study
    [4]

    Evolution of resistance to antimicrobial peptides: insights from serial passage experiments

    Perron GG, Zasloff M, Bell G · 2006

    View study
    [5]

    Anticancer activity of magainin-2 against bladder cancer cell lines and selective cytotoxicity via membrane phospholipid asymmetry

    Lehmann J, Retz M, Sidhu SS · 2006

    View study
    [6]

    Topical versus Systemic Antimicrobial Therapy for Mildly Infected Diabetic Foot Ulcers: Pexiganan Cream RCT

    Lipsky BA, et al. (Clinical Infectious Diseases) · 2008

    Cited in: Dosing

    View study
  • Mazdutide6 studies
    View page
    [1]

    Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

    Guo L, et al. · 2026

    View study
    [2]

    Mazdutide versus placebo in Chinese adults with type 2 diabetes

    Zhu D, et al. · 2026

    View study
    [3]

    Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

    Luo Y, et al. · 2026

    View study
    [4]

    Mazdutide: First Approval

    Shirley M, et al. · 2025

    View study
    [5]

    IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes

    Elmendorf AJ, et al. · 2026

    View study
    [6]

    Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1)

    Ji L, et al. (New England Journal of Medicine) · 2025

    Cited in: Dosing

    View study
  • Melanotan-210 studies
    View page
    [1]

    Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide, in a pilot phase-I clinical study

    Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME · 1996

    Cited in: Dosing

    View study
    [2]

    A synthetic analog of alpha-melanocyte stimulating hormone that is a superpotent activator of melanogenesis

    Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. · 1980

    Cited in: Dosing

    View study
    [3]

    Melanotan II - a new approach to clinical investigations of the melanocortin peptide family

    Hadley ME, Dorr RT · 2006

    Cited in: Dosing

    View study
    [4]

    Safety and efficacy of subcutaneous Melanotan-II for tanning purposes

    Ugwu SO, Blanchard J, Dorr RT, et al. · 1997

    View study
    [5]

    Initiation of human melanocyte culture through melanocortin-1 receptor with the use of an alpha-MSH analogue

    Abdel-Malek Z, Scott MC, Suzuki I, et al. · 1999

    View study
    [6]

    Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study

    Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N · 1998

    Cited in: Dosing

    View study
    [7]

    Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction

    Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N · 2000

    Cited in: Dosing

    View study
    [8]

    Melanoma associated with the use of melanotan-II

    Ellis R, et al. · 2014

    View study
    [9]

    Melanotan II injection resulting in systemic toxicity and rhabdomyolysis

    Nelson ME, Bryant SM, Aks SE · 2012

    Cited in: Dosing

    View study
    [10]

    Melanotan tanning injection: a rare cause of priapism

    Mallory C, et al. · 2021

    View study
  • MK-677 (Ibutamoren)4 studies
    View page
    [1]

    Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial

    Nass R, et al. · 2008

    Cited in: Dosing

    View study
    [2]

    Oral ghrelin receptor agonist MK-0677 increases serum IGF-1 in hemodialysis patients

    Campbell GA, et al. · 2018

    Cited in: Dosing

    View study
    [3]

    Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial

    Sevigny JJ, et al. · 2008

    View study
    [4]

    MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease

    Tian J, et al. · 2019

    View study
  • MOTS-c9 studies
    View page
    [1]

    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

    Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P · 2015

    Cited in: Is this right for me, Dosing, FAQ, Safety, Effectiveness · how it works, Hero

    View study
    [2]

    MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism

    Lee C, Kim KH, Cohen P · 2016

    Cited in: Is this right for me, Dosing, FAQ, Safety, Effectiveness · how it works

    View study
    [3]

    Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion

    Feng Y, Rao Z, Tian X, Hu Y, Yue L, Meng Y, Zhong Q, Chen W, Xu W, Li H, Hu Y, Shi R · 2024

    Cited in: Is this right for me, FAQ, Effectiveness · how it works, Hero

    View study
    [4]

    MOTS-c modulates skeletal muscle function by directly binding and activating CK2

    Kumagai H, Kim SJ, Miller B, et al. · 2024

    Cited in: Is this right for me, Effectiveness · how it works

    View study
    [5]

    MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner

    Gudiksen A, Hansen CC, van der Stede T, et al. · 2026

    Cited in: FAQ, Effectiveness · how it works

    View study
    [6]

    The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress

    Kim KH, Son JM, Benayoun BA, Lee C · 2018

    Cited in: Effectiveness · how it works

    View study
    [7]

    Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition

    D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL · 2020

    Cited in: Is this right for me, FAQ

    View study
    [8]

    MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis

    Yang L, Li M, Liu Y, Bai Y, Yin T, Chen Y, Jiang J, Liu S · 2024

    Cited in: Safety

    View study
    [9]

    Cellular and Molecular Mechanisms of Metformin Action

    LaMoia TE, Shulman GI · 2021

    Cited in: FAQ

    View study
  • Myristoyl Pentapeptide-176 studies
    View page
    [1]

    Open clinical trial evaluating efficacy of a peptide and glycosaminoglycan-based eyelash enhancer

    Fernandez-Gonzalez P, et al. · 2024

    View study
    [2]

    AP collagen peptides promote hair growth by activating the GSK-3β/β-catenin pathway

    Lee JO, et al. · 2024

    View study
    [3]

    Low molecular weight collagen peptide promotes hair growth by activating Wnt/GSK-3β/β-catenin signaling

    Kim Y, et al. · 2024

    View study
    [4]

    Hair growth promoting activity of keratin extract applied topically

    Akanda MR, et al. · 2017

    View study
    [5]

    Combination of biomimetic peptide and plant extract for modulation of alopecia

    Loing E, et al. · 2013

    View study
    [6]

    Myristoyl Pentapeptide-17 (SymPeptide 226EL) cosmetic ingredient profile

    Cosmetic Ingredients Guide · 2024

    Cited in: Dosing

    View study
  • N-Acetyl Selank6 studies
    View page
    [1]

    Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity

    Vyunova TV, Andreeva L, Shevchenko K, et al. · 2018

    Cited in: Dosing

    View study
    [2]

    GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

    Filatova EV, Shadrina MI, Slominsky PA · 2017

    View study
    [3]

    Selank Enhances the Effect of Diazepam: GABAA Receptor Subunit Study

    Kasian A, Kube E, Bhatt D · 2017

    View study
    [4]

    Selank Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content

    Kolik LG, Nadorova AV, Antipova TA, et al. · 2019

    View study
    [5]

    Functional Connectomics of Selank: Brain Network Changes Associated with Anxiolytic Peptide Administration

    Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF · 2020

    View study
    [6]

    Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank

    Medvedev VE, et al. · 2012

    Cited in: Dosing

    View study
  • N-Acetyl Semax Amidate6 studies
    View page
    [1]

    Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain

    Dolotov OV, Karpenko EA, Seredenina TS, et al. · 2006

    Cited in: Dosing

    View study
    [2]

    Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats

    Filippenkov IB, Stavchansky VV, Denisova AE · 2020

    View study
    [3]

    Brain Protein Expression Profile Confirms the Protective Effect of ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion

    Sudarkina OY, Filippenkov IB, Stavchansky VV · 2021

    View study
    [4]

    The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke

    Gusev EI, Martynov MY, Kostenko EV · 2018

    View study
    [5]

    The Effect of Semax and its C-end Peptide PGP on Expression of Neurotrophins and Their Receptors in Rat Brain During Incomplete Global Ischemia

    Stavchansky VV, Tvorogova TV, Botsina AIu · 2011

    View study
    [6]

    A nootropic adrenocorticotropin analog 4-10-Semax (15 years experience in its design and study)

    Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. · 1997

    Cited in: Dosing

    View study
  • NAD+6 studies
    View page
    [1]

    NAD+ precursor supplementation in human ageing: clinical evidence and challenges

    Vinten KT, Trætowicz MM, Coskun E · 2025

    Cited in: Dosing

    View study
    [2]

    Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial

    Yu X, Xu J, Cao J · 2026

    View study
    [3]

    NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease

    Berven H, Kverneng S, Sheard E · 2023

    View study
    [4]

    Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction

    Wang DD, Airhart SE, Zhou B · 2022

    Cited in: Dosing

    View study
    [5]

    Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease

    Szarvas Z, Reyff ZA, Peterfi A · 2025

    View study
    [6]

    Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study

    Reyna K, et al. · 2026

    Cited in: Dosing

    View study
  • Nafarelin4 studies
    View page
    [1]

    Gonadotropin releasing hormone agonists: Expanding vistas

    Magon N, et al. · 2011

    View study
    [2]

    Depressive symptoms associated with gonadotropin-releasing hormone agonists

    Warnock JK, et al. · 1998

    View study
    [3]

    Uses of GnRH agonists

    Garner C · 1994

    View study
    [4]

    SYNAREL (nafarelin acetate) nasal solution - FDA Prescribing Information / Dosage and Administration

    Pfizer / U.S. FDA · 2017

    View study
  • Natriuretic Peptide (ANP)4 studies
    View page
    [1]

    Effect of low-dose administration of carperitide for acute heart failure: the LASCAR-AHF trial

    Honda S, Nagai T, Honda Y, et al. · 2025

    View study
    [2]

    Predictors of a Good Diuretic Response and Administration Methods for Carperitide in Patients With Acute Heart Failure

    Inamoto M, Kohyama N, Suzuki H, et al. · 2024

    View study
    [3]

    The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients

    Gorący-Rosik A, Fic M, Rosik J, et al. · 2025

    View study
    [4]

    Effect of carperitide on the 1-year prognosis of patients with acute decompensated heart failure (JCS guideline dosing 0.0125-0.050 mcg/kg/min)

    Nogi K, et al. · 2022

    Cited in: Dosing

    View study
  • Nesiritide (BNP)5 studies
    View page
    [1]

    Nesiritide (Scios) - Drug Development Overview

    Burger AJ, et al. · 2002

    View study
    [2]

    Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

    O'Connor CM, et al. · 2011

    View study
    [3]

    Nesiritide — Not Verified

    Topol EJ · 2005

    View study
    [5]

    FDA Drug Approval: Natrecor (Nesiritide) NDA #20-920 Label

    U.S. Food and Drug Administration · 2001

    Cited in: Dosing

    View study
    [6]

    Natrecor (nesiritide) FUSION II / clinical dosing review: 2 mcg/kg bolus then 0.01 mcg/kg/min infusion

    Burnett JC Jr, Korinek J · 2008

    Cited in: Dosing

    View study
  • Nisin5 studies
    View page
    [1]

    Nisin, a novel lantibiotic: structure, biosynthesis and mechanism of antimicrobial activity

    Lubelski J, Rink R, Khusainov R, Moll GN, Kuipers OP · 2008

    View study
    [2]

    Nisin and its application in the food industry: a review

    Gharsallaoui A, Oulahal N, Joly C, Degraeve P · 2016

    View study
    [3]

    Anticancer activity of nisin against breast cancer cells

    Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL · 2012

    View study
    [4]

    Nisin resistance in gram-positive bacteria: mechanisms and strategies for overcoming resistance

    Zhou H, Fang J, Tian Y, Lu XY · 2014

    View study
    [5]

    Nisin-biogel against Staphylococcus aureus isolates from diabetic foot infections (topical antimicrobial concentrations)

    Jesus C, Soares R, Cunha E, Grilo M, Tavares L, Oliveira M · 2021

    Cited in: Dosing

    View study
  • Noopept (Omberacetam)6 studies
    View page
    [1]

    Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation

    Ostrovskaya RU, Vakhitova YV, Kuzmina USh · 2014

    View study
    [2]

    GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons

    Pelsman A, Hoyo-Vadillo C, Gudasheva TA · 2003

    View study
    [3]

    Noopept efficiency in experimental Alzheimer disease: cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats

    Ostrovskaya RU, Belnik AP, Storozheva ZI · 2008

    View study
    [4]

    Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) — an active pharmaceutical ingredient with nootropic activity

    Araj SK, Szeleszczuk Ł, Gubica T · 2025

    View study
    [5]

    Behavioral and electrophysiological analysis of the choline-positive effect of nootropic dipeptide acylproline (GVS-111)

    Ostrovskaya RU, Mirzoev TKh, Firova FA · 2001

    View study
    [6]

    A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment (Noopept 10 mg twice daily, 56 days)

    Neznamov GG, Teleshova ES · 2009

    Cited in: Dosing

    View study
  • Orforglipron6 studies
    View page
    [1]

    Orforglipron (LY3502970): A Phase 1a study in healthy participants

    Knop FK, Benson CT, Skarsgard JK, et al. · 2023

    View study
    [2]

    Orforglipron (LY3502970): A Phase 1b study in people with type 2 diabetes

    Pratt E, Ma X, Liu R, et al. · 2023

    View study
    [3]

    Orforglipron: A Novel Oral GLP-1 Agonist for Obesity and Diabetes

    Pillai AA, Sharma AM, Krayem H, et al. · 2025

    View study
    [4]

    Efficacy and Safety of Oral GLP-1 RA Orforglipron: A Systematic Review and Meta-Analysis

    Hammad N, Ramadan AM, Nazmy A, et al. · 2026

    View study
    [5]

    Efficacy and safety of danuglipron and orforglipron: a systematic review and meta-analysis

    Zhou J, Wang F, Li S, et al. · 2025

    View study
    [6]

    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1 phase 3; 6, 12, 36 mg once daily)

    Lilly ATTAIN-1 / NEJM · 2025

    Cited in: Dosing

    View study
  • Ovagen5 studies
    View page
    [1]

    The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology

    Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK · 2020

    View study
    [2]

    Tissue-specific effects of peptides

    Khavinson VK · 2001

    Cited in: Dosing

    View study
    [3]

    Antioxidant properties of geroprotective peptides of the pineal gland

    Kozina LS, Arutjunyan AV, Khavinson VKh · 2007

    View study
    [4]

    Short cell-penetrating peptides: a model of interactions with gene promoter sites

    Khavinson VKh, Tarnovskaya SI, Linkova NS · 2013

    View study
    [5]

    Molecular Aspects of Anti-aging Effect of Short Peptides

    Khavinson VK, Linkova NS, Tarnovskaya SI · 2021

    View study
  • Oxytocin Acetate7 studies
    View page
    [1]

    The neurobiological impact of oxytocin in mental health disorders: a comprehensive review

    Chaulagain RP, Shrestha Y, Shrestha H · 2025

    View study
    [2]

    Oxytocin in neurodevelopmental disorders: Autism spectrum disorder and Prader-Willi syndrome

    Josselsohn A, Zhao Y, Espinoza D · 2024

    View study
    [3]

    Role of Oxytocin in Different Neuropsychiatric, Neurodegenerative, and Neurodevelopmental Disorders

    Ghazy AA, Soliman OA, Elbahnasi AI · 2023

    View study
    [4]

    Effects of Intranasal Administration of Oxytocin and Vasopressin on Social Cognition and Potential Routes and Mechanisms of Action

    Yao S, Kendrick KM · 2022

    View study
    [5]

    Oxytocin and brain activity in humans: A systematic review and coordinate-based meta-analysis of functional MRI studies

    Grace SA, Rossell SL, Heinrichs M · 2018

    View study
    [6]

    Dose-dependent social-cognitive effects of intranasal oxytocin (8 IU and 24 IU) in adults with ASD

    Quintana DS, et al. · 2017

    Cited in: Dosing

    View study
    [7]

    Oxytocin (Pitocin) Dosage Guide — IV infusion for labor induction (0.5-1 milliunits/min initial)

    Drugs.com / FDA prescribing information · 2024

    Cited in: Dosing

    View study
  • P21 (P021)4 studies
    View page
    [1]

    Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice

    Li B, Wanka L, Blanchard J, Liu F, Bhatt D, Bhatt S, Bhatt A, Bhatt DK, Bhatt RS, Bhatt SP, Bhatt CK, Iqbal K, Bhatt S · 2010

    View study
    [2]

    Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease

    Kazim SF, Blanchard J, Dai CL, Bhatt A, Martinez-Martin MC, Bhatt DK, Bhatt SP, Bhatt CK, Bhatt RS, Bhatt S, Iqbal K · 2014

    View study
    [3]

    Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease

    Kazim SF, Iqbal K · 2016

    View study
    [4]

    Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

    Baazaoui N, Flory M, Bhatt DK, Bhatt SP, Iqbal K · 2017

    View study
  • PACAP-388 studies
    View page
    [1]

    More Than Three Decades After Discovery of the Neuroprotective Effect of PACAP, What Is Still Preventing Its Clinical Use?

    Cherait A, et al. · 2025

    View study
    [2]

    PACAP38 in human models of primary headaches

    Ashina H, et al. · 2017

    View study
    [3]

    Effect of Lu AG09222 on PACAP38-induced vasodilation, heart rate increase, and headache in healthy subjects

    Rasmussen NB, et al. · 2023

    View study
    [4]

    PACAP glycosides promote cell outgrowth and reduce infarct size after stroke in preclinical model

    Bernard K, et al. · 2024

    View study
    [5]

    Intranasal PACAP reduces infarct volume and promotes functional recovery after middle cerebral artery occlusion

    Cherait A, et al. · 2020

    View study
    [6]

    The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers

    Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J · 2007

    Cited in: Dosing

    View study
    [7]

    Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers

    Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, et al. · 2012

    Cited in: Dosing

    View study
    [8]

    Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial

    Al-Khazali HM, Christensen RH, Dodick DW, et al. · 2024

    Cited in: Dosing

    View study
  • Palmitoyl Oligopeptide6 studies
    View page
    [1]

    Noninvasive monitoring of palmitoyl hexapeptide-12 in human skin layers: mechanical interaction and skincare benefits

    Ligorio C, et al. · 2025

    View study
    [2]

    Self-assembly of short biopeptides onto skin tissue components studied using QCM-D

    Murthy NS, et al. · 2025

    View study
    [3]

    Synergistic effects of injectable platelet-rich fibrin and bioactive peptides on dermal fibroblast viability and ECM gene expression

    Paccola AGL, et al. · 2025

    View study
    [4]

    Bioactive peptides in cosmetic formulations: review of current in vitro and ex vivo evidence

    van Walraven N, et al. · 2025

    View study
    [5]

    Matrikines in the skin: origin, effects, and therapeutic potential

    Sirois JP, et al. · 2024

    View study
    [6]

    Safety Assessment of Tripeptide-1, Palmitoyl Tripeptide-1, and Related Palmitoyl Peptides as Used in Cosmetics

    Johnson W et al., Cosmetic Ingredient Review (CIR) Expert Panel · 2018

    Cited in: Dosing

    View study
  • Palmitoyl Pentapeptide-4 (Matrixyl)6 studies
    View page
    [1]

    Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin

    Robinson LR, et al. · 2005

    Cited in: Dosing

    View study
    [2]

    Liposome encapsulation of the Palmitoyl-KTTKS peptide: structural and functional characterization

    Vitali A, et al. · 2024

    View study
    [3]

    Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS)

    Choi YL, et al. · 2014

    View study
    [4]

    Liquid chromatography-tandem mass spectrometry to determine the stability of collagen pentapeptide (KTTKS) in rat skin

    Park EJ, et al. · 2012

    View study
    [5]

    Synergistic effects of injectable platelet-rich fibrin and bioactive peptides on dermal fibroblast viability and ECM gene expression

    Paccola AGL, et al. · 2025

    View study
    [6]

    Safety Assessment of Pentapeptide Ingredients as Used in Cosmetics

    Cosmetic Ingredient Review (CIR) Expert Panel · 2018

    Cited in: Dosing

    View study
  • Palmitoyl Tetrapeptide-76 studies
    View page
    [1]

    Peptide Bioregulation of Aging: Results and Prospects

    Khavinson VK, Linkova NS, Pronyaeva VE · 2022

    View study
    [2]

    Anti-inflammatory bioactive peptide alleviates skin inflammation by inhibiting the NF-κB signaling pathway

    Guo Z, et al. · 2025

    View study
    [3]

    Key molecular regulators in skin regeneration: PPARG, VEGFA, BGLAP, and IL6

    Tolentino JC, et al. · 2026

    View study
    [4]

    Acetyl Hexapeptide-8 in cosmeceuticals — a review of skin permeability and efficacy

    Zdrada-Nowak J, et al. · 2025

    View study
    [5]

    Current approaches in cosmeceuticals: peptides, biotics and marine biopolymers

    Badilli U, et al. · 2025

    View study
    [6]

    Safety Assessment of Tripeptide-1, Palmitoyl Tripeptide-1, and Related Palmitoyl Peptides as Used in Cosmetics

    Johnson W et al., Cosmetic Ingredient Review (CIR) Expert Panel · 2018

    Cited in: Dosing

    View study
  • Palmitoyl Tripeptide-16 studies
    View page
    [1]

    Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream

    Yang F, et al. · 2024

    View study
    [2]

    Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective

    Mortazavi SM, et al. · 2025

    View study
    [3]

    The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function

    He Q, et al. · 2024

    View study
    [4]

    Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    Pickart L, Margolina A · 2018

    View study
    [5]

    GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration

    Pickart L, et al. · 2015

    View study
    [6]

    Safety Assessment of Tripeptide-1, Palmitoyl Tripeptide-1, and Related Palmitoyl Peptides as Used in Cosmetics

    Johnson W et al., Cosmetic Ingredient Review (CIR) Expert Panel · 2018

    Cited in: Dosing

    View study
  • Pancragen5 studies
    View page
    [1]

    Effects of pancragen on the differentiation of pancreatic cells during their ageing

    Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV · 2013

    View study
    [2]

    Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys

    Goncharova ND, Ivanova LG, Oganyan TE · 2015

    View study
    [3]

    The tetrapeptide Pankragen Forte efficiency in elderly people with prediabetic state

    Korkushko OV, Chizhova VP, Shatilo VB · 2013

    Cited in: Dosing

    View study
    [4]

    Impact of tetrapeptide Pancragen on endocrine function of the pancreas in old monkeys

    Goncharova ND, Ivanova LG, Oganian TE · 2014

    View study
    [5]

    Short Peptides Regulate Gene Expression

    Khavinson VK, Lin'kova NS, Tarnovskaya SI · 2016

    View study
  • PEG-MGF6 studies
    View page
    [1]

    Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages

    Kandalla PK, Goldspink G, Butler-Browne G, Mouly V · 2011

    Cited in: Dosing

    View study
    [2]

    Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage

    Hill M, Goldspink G · 2003

    Cited in: Dosing

    View study
    [3]

    Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes

    Doroudian G, Pinney J, Ayala P, et al. · 2014

    View study
    [4]

    Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits

    Deng M, Zhang B, Wang K, et al. · 2011

    View study
    [5]

    Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise

    Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD · 2003

    View study
    [6]

    PEG-MGF Protocol — Dosing and Administration (community practice reference)

    Peptide Initiative · 2025

    Cited in: Dosing

    View study
  • Pemvidutide7 studies
    View page
    [1]

    Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

    Noureddin M, et al. · 2025

    View study
    [2]

    Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial

    Browne SK, et al. · 2025

    View study
    [3]

    Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

    Harrison SA, et al. · 2025

    View study
    [4]

    Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs

    Kaya E, et al. · 2025

    View study
    [5]

    Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

    Nestor JJ, et al. · 2022

    View study
    [6]

    262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity - A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

    Aronne L, Harris MS, Roberts MS, Suschak JJ, Tomah S, Kasper J, He L, Yang J, Frias JP, Browne SK · 2024

    Cited in: Dosing

    View study
    [7]

    Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

    Altimmune, Inc. · 2025

    Cited in: Dosing

    View study
  • Pentadecapeptide (BPC Analog)5 studies
    View page
    [1]

    Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing

    McGuire FP, et al. · 2025

    Cited in: Dosing

    View study
    [2]

    Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

    Vasireddi N, et al. · 2025

    Cited in: Dosing

    View study
    [3]

    Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing

    Gwyer D, et al. · 2019

    Cited in: Dosing

    View study
    [4]

    Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro

    Huang T, et al. · 2015

    View study
    [5]

    Effect of BPC 157 on tendon healing

    Chang et al. · 2011

    View study
  • Pidotimod6 studies
    View page
    [1]

    Reappraisal of Pidotimod: an immunomodulatory agent with 30-year evidence

    Marseglia GL, Gelardi M, Santus P · 2024

    View study
    [2]

    Pidotimod in pediatrics: new evidence and future perspectives

    Ciprandi G, Marseglia GL · 2024

    Cited in: Dosing

    View study
    [3]

    Pidotimod and Immunological Activation in Individuals Infected with HIV

    Ucciferri C, Falasca K, Reale M · 2021

    View study
    [4]

    Analysis of Factors and T-Lymphocyte Subset Changes in Pediatric Recurrent Respiratory Infections Post-Pidotimod Treatment

    Hu R, Jin C, Lin X · 2025

    View study
    [5]

    Pidotimod: the past and the present

    Zuccotti GV, Mameli C · 2013

    Cited in: Dosing

    View study
    [6]

    Pidotimod: the immunomodulatory agent - an in-depth review of current evidence

    Ferrario BE, Garuti S, Braido F, Canonica GW · 2015

    Cited in: Dosing

    View study
  • Pinealon6 studies
    View page
    [1]

    Molecular Mechanisms of Action of Short Peptides for the Treatment of Alzheimer's Disease

    Khavinson V, Linkova N, Kozhevnikova E · 2021

    View study
    [2]

    Molecular Basis of Specific Interaction of Short Peptides with DNA

    Khavinson VK, Tendler SM, Vanyushin BF · 2014

    View study
    [3]

    Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease

    Kraskovskaya NA, Kukanova EO, Lin'kova NS · 2017

    View study
    [4]

    Neuroprotective Properties of Short Peptides on the Model of Early Huntington's Disease

    Khavinson V, Lin'kova NS, Kukanova EO · 2019

    View study
    [5]

    Short Peptides Stimulate Serotonin Expression in Cells of Brain Cortex

    Khavinson V, Lin'kova NS, Tarnovskaya SI · 2014

    View study
    [6]

    Encapsulated Delivery of Regulatory (EDR) Peptide Pinealon: Review

    Khavinson et al. · 2021

    Cited in: Dosing

    View study
  • PNC-275 studies
    View page
    [1]

    PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis

    Sarafraz-Yazdi E, Mumin S, Engel D, et al. · 2022

    View study
    [2]

    Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells

    Thadi A, Forber M, Engel D, et al. · 2020

    View study
    [3]

    Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells

    Thadi A, Esposito M, Bhargava S, et al. · 2021

    View study
    [4]

    The Anti-Cancer Peptide, PNC-27, Induces Tumor Cell Lysis as the Intact Peptide

    Bowne WB, Michl J, Sookraj KA, et al. · 2014

    View study
    [5]

    Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes

    Sookraj KA, Bowne WB, Adler V, et al. · 2010

    View study
  • Polymyxin B6 studies
    View page
    [1]

    Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications

    Zavascki AP, Goldani LZ, Li J, Nation RL · 2007

    View study
    [2]

    Nephrotoxicity associated with intravenous polymyxin B: a systematic review and meta-analysis

    Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M · 2015

    View study
    [3]

    Therapeutic drug monitoring of polymyxin B: target exposure and optimal dosing strategies

    Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A · 2019

    Cited in: Dosing

    View study
    [4]

    Polymyxin B for the treatment of multidrug-resistant Gram-negative infections: clinical outcomes and resistance mechanisms

    Elias LS, Konzen D, Krebs JM, Zavascki AP · 2010

    View study
    [5]

    Polymyxin combination therapy for carbapenem-resistant organisms: systematic review and network meta-analysis

    Ni W, Han Y, Liu J, Wei C, Zhao J, Cui J, Wang R, Liu Y · 2022

    View study
    [6]

    Polymyxin B Sulfate for Injection USP - FDA Prescribing Information (DailyMed)

    X-Gen Pharmaceuticals · 2012

    Cited in: Dosing

    View study
  • Pralmorelin (GHRP-2)4 studies
    View page
    [1]

    Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.

    Suzuki S, Ruike Y, Ishiwata K, et al. · 2022

    Cited in: Dosing

    View study
    [2]

    Robust growth hormone responses to GH-releasing peptide 2 in adolescents.

    Onuki T, Hiroaki T, Sawano K, et al. · 2024

    View study
    [3]

    Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Tendon-Bone Healing in Rat Rotator Cuff Model.

    Li Y, Yao L, Zhang C, et al. · 2025

    View study
    [4]

    GHRP-2, like ghrelin, increases food intake in healthy men

    Laferrere B, Abraham C, Russell CD, Bowers CY · 2005

    Cited in: Dosing

    View study
  • Pramlintide6 studies
    View page
    [1]

    Pramlintide as an Adjunct to Insulin Therapy in Type 2 Diabetes: Systematic Review and Meta-Analysis

    Singh-Franco D, Perez A, Harrington C · 2024

    View study
    [2]

    Pramlintide for the Treatment of Type 1 and Type 2 Diabetes Mellitus

    Younk LM, Mikeladze M, Davis SN · 2011

    View study
    [3]

    Amylin Physiology and Its Role in Diabetes Management

    Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD · 2015

    View study
    [4]

    Pramlintide: A Review of Its Use in the Management of Insulin-Requiring Diabetes Mellitus

    Ryan GJ, Jobe LJ, Martin R · 2005

    View study
    [5]

    Pramlintide Acetate: An Adjunctive Therapy for Type 1 and Type 2 Diabetes

    Schmitz O, Brock B, Rungby J · 2004

    View study
    [6]

    SYMLIN (pramlintide acetate) injection - FDA Prescribing Information (DailyMed)

    AstraZeneca Pharmaceuticals · 2015

    Cited in: Dosing

    View study
  • Prostamax6 studies
    View page
    [1]

    Bioregulator Peptides and Prostatic Function in Aging Males

    Khavinson VK, Ryzhak GA · 2012

    Cited in: Dosing

    View study
    [2]

    Peptide Bioregulation of Prostatic Tissue Differentiation

    Khavinson VK, Morozov VG · 2002

    View study
    [3]

    Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

    Avolio F, Martinotti S, Khavinson VK · 2022

    View study
    [4]

    Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures

    Khavinson VK, Linkova NS, Kvetnoy IM · 2013

    View study
    [5]

    Geroprotective Effect of Thymalin and Epithalon

    Khavinson VK, Morozov VG · 2003

    View study
    [6]

    Agent possessing prostatotropic activity (KEDP peptide) - Patent RU2177802C1

    Khavinson V.Kh. et al. · 2002

    Cited in: Dosing

    View study
  • PT-141 (Bremelanotide)6 studies
    View page
    [1]

    Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Kingsberg SA, Clayton AH, Portman D · 2019

    Cited in: Dosing

    View study
    [2]

    Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

    Simon JA, Kingsberg SA, Portman D · 2019

    View study
    [3]

    Bremelanotide: First Approval

    Dhillon S, Keam SJ · 2019

    View study
    [4]

    The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women

    Pfaus JG, Sadiq A, Spana C · 2022

    View study
    [5]

    The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results

    Koochaki P, Revicki D, Wilson H · 2021

    View study
    [6]

    VYLEESI (bremelanotide injection) US Prescribing Information

    AMAG Pharmaceuticals (FDA) · 2019

    Cited in: Dosing

    View study
  • Relaxin-2 (Serelaxin)5 studies
    View page
    [1]

    End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)

    Voors AA, et al. · 2025

    View study
    [2]

    Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice

    Martins RC, et al. · 2020

    View study
    [3]

    Effects of Serelaxin in Patients with Acute Heart Failure

    Metra M, et al. · 2019

    Cited in: Dosing

    View study
    [4]

    Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU

    Maggioni AP, et al. · 2019

    View study
    [5]

    Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

    Teerlink JR, Cotter G, Davison BA, et al. · 2013

    Cited in: Dosing

    View study
  • Retatrutide14 studies
    View page
    [1]

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

    Jastreboff AM, Kaplan LM, Frías JP et al. · 2023

    Cited in: Is this right for me, Dosing, FAQ, Safety, Safety · side effects, Effectiveness · timeline, Effectiveness · troubleshooting, Hero

    View study
    [2]

    A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity

    Kaur M, Misra S · 2024

    Cited in: FAQ, Effectiveness · how it works, Dosing · timing, Hero

    View study
    [3]

    Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis

    Tewari J, Qidwai KA, Tewari A et al. · 2025

    Cited in: Dosing, Safety, Safety · side effects, Effectiveness · troubleshooting

    View study
    [4]

    Effects of retatrutide on body composition in people with type 2 diabetes

    Coskun T, Wu Q, Schloot NC et al. · 2025

    Cited in: Effectiveness · timeline

    View study
    [5]

    Triple Agonism Based Therapies for Obesity

    Goldney J, Hamza M, Surti F · 2025

    Cited in: Is this right for me

    View study
    [6]

    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

    Rosenstock J, Frias J, Jastreboff AM et al. · 2023

    Cited in: Is this right for me, Safety, Dosing · timing

    View study
    [7]

    Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

    Sanyal AJ, Kaplan LM, Frias JP et al. · 2024

    Cited in: Is this right for me

    View study
    [8]

    Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

    Sodhi M, Rezaeianzadeh R, Kezouh A et al. · 2023

    Cited in: Safety · side effects

    View study
    [9]

    Gallstone formation during weight-reduction dieting

    Liddle RA, Goldstein RB, Saxton J · 1989

    Cited in: Safety · side effects

    View study
    [10]

    Tirzepatide Once Weekly for the Treatment of Obesity

    Jastreboff AM, Aronne LJ, Ahmad NN et al. · 2022

    Cited in: FAQ

    View study
    [11]

    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

    Giblin K, Kaplan LM, Somers VK et al. · 2025

    Cited in: FAQ

    View study
    [12]

    Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    Wilding JPH, Batterham RL, Davies M et al. · 2022

    Cited in: FAQ

    View study
    [13]

    Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

    Bjerre Knudsen L, Madsen LW, Andersen S et al. · 2010

    Cited in: FAQ

    View study
    [14]

    Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

    Wilding JPH, Batterham RL, Calanna S, et al. · 2021

    Cited in: FAQ

    View study
  • Selank7 studies
    View page
    [1]

    Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity

    Vyunova TV, Andreeva L, Shevchenko K, et al. · 2018

    Cited in: Dosing · adjustment, Is this right for me, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline, Hero

    View study
    [2]

    Selank Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content

    Kolik LG, Nadorova AV, Antipova TA, et al. · 2019

    Cited in: Is this right for me, Effectiveness · how it works

    View study
    [3]

    A Comparison of the Anxiolytic Effect and Tolerability of Selank and Phenazepam

    Medvedev VE, Tereshchenko ON, Israelian AIu, et al. · 2014

    Cited in: Dosing, FAQ, Safety, Effectiveness · timeline

    View study
    [4]

    Expression of Inflammation-Related Genes in Mouse Spleen Under Tuftsin Analog Selank

    Kolomin T, Shadrina M, Andreeva L, et al. · 2011

    Cited in: Is this right for me, Effectiveness · how it works, Hero

    View study
    [5]

    Immunomodulatory Effects of Selank in Patients with Anxiety-Asthenic Disorders

    Uchakina ON, Uchakin PN, Miasoedov NF, et al. · 2008

    Cited in: Dosing, Safety, Effectiveness · how it works

    View study
    [6]

    The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity

    Zozulya AA, Kost NV, Sokolov OY, et al. · 2001

    Cited in: Effectiveness · how it works

    View study
    [7]

    Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments

    Kolomin TA, Shadrina MI, Slominsky PA, et al. · 2011

    Cited in: Effectiveness · how it works

    View study
  • Semaglutide6 studies
    View page
    [1]

    Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

    Wilding JPH, Batterham RL, Calanna S, et al. · 2021

    View study
    [2]

    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · 2023

    View study
    [3]

    Semaglutide from Bench to Bedside: The Experimental Journey

    Weiskirchen R, Lonardo A · 2025

    View study
    [4]

    Tirzepatide vs. Semaglutide: Clinical Decision-Making in the GLP-1 Landscape

    Mondoh A, Crotty M, le Roux CW · 2025

    View study
    [5]

    OZEMPIC (semaglutide injection) Prescribing Information

    Novo Nordisk / U.S. FDA · 2025

    Cited in: Dosing

    View study
    [6]

    RYBELSUS (oral semaglutide tablets) Prescribing Information

    Novo Nordisk / U.S. FDA · 2024

    Cited in: Dosing

    View study
  • Semax5 studies
    View page
    [1]

    Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus

    Dolotov OV, Karpenko EA, Inozemtseva LS, et al. · 2006

    Cited in: Dosing

    View study
    [2]

    Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain

    Dolotov OV, Karpenko EA, Seredenina TS, et al. · 2006

    Cited in: Dosing

    View study
    [3]

    Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action

    Shadrina M, Kolomin T, Agapova T, et al. · 2010

    Cited in: Dosing

    View study
    [4]

    Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity

    Tabbi G, Magri A, Giuffrida A, et al. · 2015

    View study
    [5]

    The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease

    Radchenko AI, Kuzubova EV, Apostol AA · 2025

    View study
  • Sermorelin5 studies
    View page
    [1]

    Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men

    Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR · 1992

    Cited in: Dosing

    View study
    [2]

    Endocrine and metabolic effects of long-term administration of GHRH-(1-29)-NH2 in age-advanced men and women

    Khorram O, Laughlin GA, Yen SS · 1997

    Cited in: Dosing

    View study
    [3]

    Effects of single nightly injections of GHRH (1-29) in healthy elderly men

    Vittone J, Blackman MR, Busby-Whitehead J, et al. · 1997

    Cited in: Dosing

    View study
    [4]

    In vivo semiquantification of hypothalamic GHRH output in humans: evidence for relative GHRH deficiency in aging

    Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL · 1999

    View study
    [5]

    Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels

    Sigalos JT, Pastuszak AW, Allison A, Khera M · 2017

    View study
  • Setmelanotide6 studies
    View page
    [1]

    Setmelanotide: First Approval

    Markham A · 2021

    Cited in: Dosing

    View study
    [2]

    Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE)

    Argente J, Verge CF, Okorie U, et al. · 2025

    Cited in: Dosing

    View study
    [3]

    Setmelanotide: A Melanocortin-4 Receptor Agonist for Severe Obesity Due to Hypothalamic Dysfunction

    Qamar S, Mallik R, Makaronidis J, et al. · 2024

    Cited in: Dosing

    View study
    [4]

    The effect of MC4R agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis

    Sun Y, Abed M, Sohouli MH, et al. · 2025

    View study
    [5]

    Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways

    Peng J, Ou Y, Zhou M, et al. · 2025

    View study
    [6]

    IMCIVREE (setmelanotide injection) US Prescribing Information

    Rhythm Pharmaceuticals (FDA / DailyMed) · 2024

    Cited in: Dosing

    View study
  • SLU-PP-3324 studies
    View page
    [1]

    Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity

    Billon C, Sitaula S, Banerjee S, et al. · 2023

    Cited in: Dosing

    View study
    [2]

    A Synthetic ERR Agonist Alleviates Metabolic Syndrome

    Billon C, Schoepke E, Avdagic A, et al. · 2024

    Cited in: Dosing

    View study
    [3]

    An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity

    Billon C, Appourchaux K, Côté I, et al. · 2025

    View study
    [4]

    The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB

    Losby M, Hayes M, Valfort A, et al. · 2024

    View study
  • SM-1306863 studies
    View page
    [1]

    Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686

    Nagamine J et al. · 2001

    View study
    [2]

    Synthesis and pharmacological profile of SM-130686 and related compounds

    Nagamine J et al. · 2006

    View study
    [3]

    Common structural basis for constitutive activity of the ghrelin receptor family

    Holst B et al. · 2009

    View study
  • Snap-85 studies
    View page
    [1]

    Non-Invasive Peptides as the Future of Botox Alternatives

    Cosmetics MDPI Review · 2024

    Cited in: Dosing

    View study
    [2]

    Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects

    Park JH, et al. · 2024

    View study
    [3]

    Topical delivery of acetyl hexapeptide-8 from different emulsions

    Hoppel M, Reznicek G, Kahlig H · 2015

    View study
    [4]

    In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation

    Kraeling ME, Zhou W, Wang P · 2015

    View study
    [5]

    Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis

    Olsson SE, Sreepad B, Lee T · 2024

    View study
  • SS-31 (Elamipretide)16 studies
    View page
    [1]

    Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential

    Tung C, Varzideh F, Farroni E · 2025

    Cited in: Is this right for me, FAQ, Safety, Effectiveness · how it works, Dosing · timing, Hero

    View study
    [2]

    Mitochondrial protein interaction landscape of SS-31

    Chavez JD, Tang X, Campbell MD · 2020

    Cited in: Is this right for me, FAQ, Effectiveness · how it works

    View study
    [3]

    Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds

    Mitchell W, Tamucci JD, Ng EL · 2022

    Cited in: FAQ, Effectiveness · how it works

    View study
    [4]

    SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis in Mice

    Gu Q, Wang Y, Zhang H · 2025

    View study
    [5]

    Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury

    Ravenscraft B, Lee DH, Dai H · 2025

    Cited in: FAQ, Effectiveness · how it works

    View study
    [6]

    A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome

    Reid Thompson W, Hornby B, Manuel R, et al. · 2021

    Cited in: Dosing, Safety

    View study
    [7]

    SS-31 (Elamipretide/Bendavia): mechanism, clinical pharmacology and intravenous dosing review

    Cognitive Vitality (ADDF) · 2019

    Cited in: Dosing, Safety · side effects

    View study
    [8]

    FORZINITY (elamipretide) injection, for subcutaneous use - FDA prescribing information

    U.S. Food and Drug Administration · 2025

    Cited in: FAQ, Safety

    View study
    [9]

    Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY (elamipretide HCl), the First Therapy for Barth Syndrome

    Stealth BioTherapeutics · 2025

    Cited in: FAQ, Safety

    View study
    [10]

    Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

    Karaa A, Bertini E, Carelli V · 2023

    Cited in: FAQ, Safety, Safety · side effects

    View study
    [11]

    The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action

    Mitchell W, Ng EA, Tamucci JD · 2020

    Cited in: Effectiveness · how it works

    View study
    [12]

    Cardiolipin, the Mitochondrial Signature Lipid: Implication in Cancer

    Ahmadpour ST, Maheo K, Servais S · 2020

    Cited in: Effectiveness · how it works

    View study
    [13]

    Role of cardiolipin in skeletal muscle function and its therapeutic implications

    Yoo Y, Yeon M, Yoon MS · 2025

    Cited in: Effectiveness · how it works

    View study
    [14]

    Interactions between mitochondrial dysfunction and other hallmarks of aging: Paving a path toward interventions that promote healthy old age

    Li Y, Berliocchi L, Li Z · 2023

    Cited in: Is this right for me

    View study
    [15]

    SS-31 and NMN: Two paths to improve metabolism and function in aged hearts

    Whitson JA, Bitto A, Zhang H · 2020

    Cited in: Dosing · timing

    View study
    [16]

    Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness

    Smuder AJ, Roberts BM, Wiggs MP · 2020

    Cited in: FAQ

    View study
  • Substance P Antagonists5 studies
    View page
    [1]

    Involvement of ASIC3 and Substance P in Therapeutic Ultrasound-Mediated Analgesia in Mouse Models of Fibromyalgia

    Han DS, et al. · 2023

    View study
    [2]

    Involvement of the substance P/neurokinin-1 receptor system in oral pain and inflammation

    Velasco-Ortega E, et al. · 2020

    View study
    [3]

    Advances in the research and application of neurokinin-1 receptor antagonists

    Hong X, et al. · 2024

    View study
    [4]

    Trigeminal nerve-driven neurogenic inflammation linking migraine to glioblastoma invasion: a literature review

    Song X, et al. · 2025

    View study
    [5]

    EMEND (aprepitant) capsules and EMEND for injection (fosaprepitant) Prescribing Information

    Merck & Co. / U.S. FDA · 2010

    Cited in: Dosing

    View study
  • Survodutide5 studies
    View page
    [1]

    Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

    le Roux CW, Steen O, Lucas KJ, et al. · 2024

    Cited in: Dosing

    View study
    [2]

    Dose-response effects on HbA1c and bodyweight reduction of survodutide compared with placebo and open-label semaglutide in type 2 diabetes

    Blüher M, Rosenstock J, Hoefler J, et al. · 2024

    View study
    [3]

    BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

    Zimmerman T, et al. · 2022

    View study
    [4]

    Survodutide for the Treatment of Obesity: Design of the SYNCHRONIZE CVOT

    Kosiborod MN, Platz E, Wharton S, et al. · 2024

    View study
    [5]

    The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection

    Thomas L, Martel E, Rist W, et al. · 2024

    View study
  • SYN-AKE6 studies
    View page
    [1]

    Anti-aging activity of SYN-AKE peptide by in silico approaches and in vitro tests

    Gok B, et al. · 2024

    View study
    [2]

    Viper venom Botox: molecular origin and evolution of waglerin peptides used in anti-wrinkle skin cream

    Debono J, et al. · 2017

    View study
    [3]

    Real-world clinical experience with neuro-peptide serum in combination with botulinum toxin Type-A injections

    Lupin M, et al. · 2024

    View study
    [4]

    Residues in the epsilon subunit of nAChR interact to confer selectivity of waglerin-1 for the alpha-epsilon interface

    Molles BE, et al. · 2002

    View study
    [5]

    Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor

    McArdle JJ, et al. · 1999

    View study
    [6]

    SYN-AKE formulation guidelines and in-vivo efficacy data (4% use level)

    DSM Personal Care · 2020

    Cited in: Dosing

    View study
  • Tabimorelin3 studies
    View page
    [1]

    The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers

    Zdravkovic M, et al. · 2000

    Cited in: Dosing

    View study
    [2]

    Oral administration of NN703 in adult patients with growth hormone deficiency

    Svensson J, et al. · 2003

    Cited in: Dosing

    View study
    [3]

    Pharmacokinetic and pharmacodynamic modeling of NN703 after a single oral dose to human volunteers

    Agersø H, et al. · 2001

    View study
  • TB-5006 studies
    View page
    [1]

    Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications

    Goldstein AL, Hannappel E, Sosne G · 2012

    View study
    [2]

    Advances in the basic and clinical applications of thymosin beta4

    Goldstein AL, Kleinman HK · 2015

    View study
    [3]

    Neuroprotective and neurorestorative effects of thymosin beta4 treatment following experimental traumatic brain injury

    Xiong Y, Mahmood A, Meng Y, et al. · 2012

    View study
    [4]

    Thymosin beta4 and the anti-fibrotic switch

    Kleinman HK, Kulik V, Goldstein AL · 2023

    View study
    [5]

    Thymosin beta4 promotes endothelial progenitor cell angiogenesis via a vascular endothelial growth factor-dependent mechanism

    Zhao Y, Song J, Bi X, et al. · 2018

    View study
    [6]

    TB-500 (Thymosin Beta-4) research-use dosing protocol and reconstitution guide

    Peptide Dosing Protocols · 2026

    Cited in: Dosing

    View study
  • Tesamorelin16 studies
    View page
    [1]

    Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials

    Falutz J, Mamputu JC, Potvin D, et al. · 2010

    Cited in: Dosing · adjustment, Is this right for me, Dosing, Effectiveness · signs, FAQ, Safety, Effectiveness · how it works, Effectiveness · timeline, Effectiveness · troubleshooting

    View study
    [2]

    Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin

    Stanley TL, Falutz J, Marsolais C, et al. · 2012

    Cited in: Is this right for me, Effectiveness · signs, Effectiveness · timeline

    View study
    [3]

    Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

    Baker LD, Barsness SM, Borson S, et al. · 2012

    Cited in: FAQ, Effectiveness · how it works, Effectiveness · timeline

    View study
    [4]

    Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

    Stanley TL, Fourman LT, Feldpausch MN, et al. · 2019

    Cited in: Is this right for me

    View study
    [5]

    Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy

    Dhillon S · 2011

    Cited in: Is this right for me, FAQ, Effectiveness · how it works, Effectiveness · timeline, Effectiveness · troubleshooting

    View study
    [6]

    EGRIFTA SV (tesamorelin for injection) Prescribing Information

    Theratechnologies Inc. / U.S. FDA · 2019

    Cited in: Is this right for me, Dosing, FAQ, Safety, Effectiveness · how it works, Safety · side effects, Effectiveness · timeline, Safety · when to stop, Hero

    View study
    [7]

    Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

    Falutz J, Potvin D, Mamputu JC, et al. · 2010

    Cited in: FAQ, Effectiveness · timeline

    View study
    [8]

    Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue

    Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P · 2007

    Cited in: Effectiveness · how it works

    View study
    [9]

    Growth hormone-releasing hormone receptor (GHRH-R) and its signaling

    Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV · 2025

    Cited in: Effectiveness · how it works

    View study
    [10]

    Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies

    Stanley TL, Grinspoon SK · 2015

    Cited in: Is this right for me, FAQ, Effectiveness · how it works

    View study
    [11]

    Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial

    Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK · 2012

    Cited in: FAQ, Effectiveness · timeline

    View study
    [12]

    Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

    Neeland IJ, Ross R, Despres JP, et al. · 2019

    Cited in: Is this right for me

    View study
    [13]

    The enigmatic role of growth hormone in age-related diseases, cognition, and longevity

    Colon G, Saccon T, Schneider A, et al. · 2019

    Cited in: Effectiveness · how it works

    View study
    [14]

    Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement

    Reed ML, Merriam GR, Kargi AY · 2013

    Cited in: FAQ, Safety · side effects

    View study
    [15]

    Human growth hormone receptor (GHR) expression in obesity: I. GHR mRNA expression in omental and subcutaneous adipose tissues of obese women

    Erman A, Veilleux A, Tchernof A, Goodyer CG · 2011

    Cited in: Effectiveness · how it works

    View study
    [16]

    Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men

    Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T · 2000

    Cited in: FAQ

    View study
  • Testagen5 studies
    View page
    [1]

    Peptide Bioregulation of Aging: Results and Prospects

    Khavinson VK, Linkova NS, Pronyaeva VE · 2022

    Cited in: Dosing

    View study
    [2]

    Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

    Avolio F, Martinotti S, Khavinson VK · 2022

    View study
    [3]

    Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease

    Khavinson VK, Lin'kova NS, Umnov RS · 2021

    View study
    [4]

    Peptide Geroprotectors — Epigenetic Regulators

    Khavinson VK, Linkova NS, Diatlova A · 2019

    View study
    [5]

    Geroprotective Effect of Thymalin and Epithalon

    Khavinson VK, Morozov VG · 2003

    View study
  • Thymalin4 studies
    View page
    [1]

    Thymalin: Immune modulation and therapeutic potential in aging

    Khavinson VH, et al. · 2020

    Cited in: Dosing

    View study
    [2]

    Peptide thymus extract improves immune markers in chronic diseases

    Loginova NN, et al. · 2018

    View study
    [3]

    Thymopoietin-derived peptide Thymalin restores immune tolerance

    Solopova IA, et al. · 2016

    View study
    [4]

    Thymalin supports immune recovery during cancer treatment

    Anisimova EA, et al. · 2021

    View study
  • Thymopentin (TP-5)5 studies
    View page
    [1]

    Thymopentin (TP-5) enhances immune function in HIV and cancer patients

    Jiang Y, et al. · 2015

    View study
    [2]

    Thymopentin modulates T cell receptor signaling and immune tolerance

    Valone FH, et al. · 2017

    View study
    [3]

    Thymopentin peptide in age-related immune decline and vaccination response

    Provinciali M, et al. · 2019

    View study
    [4]

    TP-5 prevents chemotherapy-induced immunosuppression

    Gaidano G, et al. · 2014

    View study
    [5]

    Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial

    Goldstein G, et al. · 1995

    Cited in: Dosing

    View study
  • Thymopoietin5 studies
    View page
    [1]

    Thymopoietin: The parent thymic hormone and its immune restoration properties

    Goldstein G, et al. · 2015

    View study
    [2]

    Thymopoietin peptide fragments enhance both cellular and humoral immunity

    Hadden JW, et al. · 2016

    View study
    [3]

    Thymopoietin restores T cell receptor-mediated signaling in aging

    Sempowski GD, et al. · 2018

    View study
    [4]

    Thymopoietin peptides in immune recovery during HIV and cancer treatment

    Sereti I, et al. · 2017

    View study
    [5]

    Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial

    Goldstein G, et al. · 1995

    Cited in: Dosing

    View study
  • Thymosin Alpha-16 studies
    View page
    [1]

    Historical review on thymosin α1 in oncology: preclinical and clinical experiences

    Garaci E, Pica F, Matteucci C · 2015

    View study
    [2]

    Jack of all trades: thymosin α1 and its pleiotropy

    Romani L, Moretti S, Fallarino F · 2012

    View study
    [3]

    Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure

    Chen JF, Chen SR, Lei ZY · 2022

    View study
    [4]

    Thymosin alpha-1 (Review)

    Ancell CD, Phipps J, Young L · 2001

    Cited in: Dosing

    View study
    [5]

    Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

    Clinical Trial NCT04428008 · 2023

    View study
    [6]

    Thymalfasin for the treatment of chronic hepatitis B

    Iino S, Toyota J, Kumada H, et al. · 2004

    Cited in: Dosing

    View study
  • Thymosin Beta-46 studies
    View page
    [1]

    Thymosin β4: A multifunctional immunoregulatory and tissue-repair peptide

    Sosne G, et al. · 2016

    Cited in: Dosing

    View study
    [2]

    Thymosin β4 in tissue repair and regeneration: Activin A signaling

    Metcalfe JC, et al. · 2015

    View study
    [3]

    Thymosin β4 cardioprotection and myocardial repair mechanisms

    Philp D, et al. · 2017

    View study
    [4]

    Thymosin β4 enhances immune response and protects against sepsis

    Brown DM, et al. · 2018

    View study
    [5]

    0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing in Neurotrophic Keratopathy: a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

    Sosne G, Ousler GW, et al. · 2022

    Cited in: Dosing

    View study
    [6]

    A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 (RGN-352) for Treating Acute Myocardial Infarction

    RegeneRx Biopharmaceuticals (NCT01311518) · 2011

    Cited in: Dosing

    View study
  • Thymulin (FTS)4 studies
    View page
    [1]

    Physiology and therapeutic potential of the thymic peptide thymulin

    Bach JF, et al. · 2014

    Cited in: Dosing

    View study
    [2]

    Thymulin promotes Th1 differentiation and IFN-γ production in aging T cells

    Fabris N, et al. · 2017

    View study
    [3]

    Thymulin zinc-binding and immune function restoration

    Prasad AS, et al. · 2015

    View study
    [4]

    Thymulin supports immune recovery during infection and chemotherapy

    Dardenne M, et al. · 2018

    View study
  • Thymulin Analog (PAT)5 studies
    View page
    [1]

    Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide

    Safieh-Garabedian B, et al. · 2019

    View study
    [2]

    Involvement of alpha-7 nicotinic acetylcholine receptors in the anti-inflammatory action of PAT

    Safieh-Garabedian B, et al. · 2013

    View study
    [3]

    Role of thymulin or its analogue as a new analgesic molecule

    Dardenne M, et al. · 2006

    View study
    [4]

    A thymulin analogue peptide with powerful inhibitory effects on pain of neurogenic origin

    Saadé NE, et al. · 2003

    View study
    [5]

    Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat

    Safieh-Garabedian B, et al. · 2002

    View study
  • Tirzepatide5 studies
    View page
    [1]

    Tirzepatide Once Weekly for the Treatment of Obesity

    Jastreboff AM, Aronne LJ, Ahmad NN et al. · 2022

    Cited in: Dosing

    View study
    [2]

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

    Frías JP, Davies MJ, Rosenstock J, et al. · 2021

    View study
    [3]

    Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)

    Wadden TA, Chao AM, Machineni S, et al. · 2023

    View study
    [4]

    Effects of Tirzepatide on Cardiometabolic Risk Factors

    Sattar N, McGuire DK, Pavo I, et al. · 2022

    View study
    [5]

    MOUNJARO (tirzepatide) injection, for subcutaneous use - FDA Prescribing Information

    Eli Lilly and Company · 2025

    Cited in: Dosing

    View study
  • Tripeptide-296 studies
    View page
    [1]

    Gly-Pro-Hyp as a potent anti-photoaging peptide: effects on UV-induced photoaging in collagen hydrolysate studies

    Yang D, et al. · 2024

    Cited in: Dosing

    View study
    [2]

    Pharmacokinetics of collagen tripeptide Gly-Pro-Hyp: oral bioavailability and tissue distribution

    Won J, et al. · 2024

    View study
    [3]

    Oral collagen hydrolysate leads to transportation of Gly-Pro-Hyp into the bloodstream and skin

    Yazaki M, et al. · 2017

    View study
    [4]

    Low-molecular-weight collagen peptide improves hydration, elasticity, and wrinkling: randomized double-blind placebo-controlled study

    Kim DU, et al. · 2018

    View study
    [5]

    Bioactive collagen hydrolysates enhance facial skin moisture and elasticity: randomized double-blind placebo-controlled trial

    Inoue N, et al. · 2016

    View study
    [6]

    Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin: A Randomized, Double-Blind, Placebo-Controlled Study

    Kim DU, Chung HC, Choi J, Sakai Y, Lee BY · 2018

    Cited in: Dosing

    View study
  • Triptorelin6 studies
    View page
    [1]

    Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data

    Jia W, Wang T · 2025

    View study
    [2]

    A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia

    Yee CH, Chung YH, Ko IC · 2025

    View study
    [3]

    Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China

    Chen Y, Pan J, Zhong Y · 2024

    View study
    [4]

    Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer

    Patel S, Zhu K, Dave CV · 2025

    View study
    [5]

    TRELSTAR (triptorelin pamoate) for injectable suspension — FDA Prescribing Information

    Verity Pharmaceuticals / U.S. Food and Drug Administration · 2023

    Cited in: Dosing

    View study
    [6]

    TRIPTODUR (triptorelin) for extended-release injectable suspension — FDA Prescribing Information

    Azurity Pharmaceuticals / U.S. Food and Drug Administration · 2022

    Cited in: Dosing

    View study
  • Ularitide6 studies
    View page
    [1]

    Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis

    Mitrovic V, Forssmann WG, Schnitker J · 2018

    View study
    [2]

    Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies

    Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G · 2015

    View study
    [3]

    New Pharmacotherapeutic Classes for the Management of Heart Failure: A Narrative Review

    Haryani A, Sangwan A · 2024

    View study
    [4]

    Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?

    Pollesello P, Ben Gal T, Bettex D · 2019

    View study
    [5]

    Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis

    Dai H, Li H, Wang B · 2022

    View study
    [6]

    Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF)

    Packer M, O'Connor C, McMurray JJV, et al. · 2017

    Cited in: Dosing

    View study
  • Urocortin7 studies
    View page
    [1]

    Corticotropin-Releasing Hormone Family and Their Receptors in the Cardiovascular System

    Takefuji M, Murohara T · 2019

    View study
    [2]

    Do urocortins have a role in treating cardiovascular disease?

    Chatzaki E, Kefala N, Drosos I · 2019

    View study
    [3]

    Effects of Urocortin 2 Versus Urocortin 3 Gene Transfer on Left Ventricular Function and Glucose Disposal

    Giamouridis D, Gao MH, Lai NC · 2018

    View study
    [4]

    Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension

    Adão R, Mendes-Ferreira P, Santos-Ribeiro D · 2018

    View study
    [5]

    Urocortins: Actions in health and heart failure

    Rademaker MT, Richards AM · 2017

    View study
    [6]

    Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study

    Chan WYW, Frampton CM, Crozier IG, Troughton RW, Richards AM · 2013

    Cited in: Dosing

    View study
    [7]

    Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure

    Stirrat CG, Venkatasubramanian S, Pawade T, et al. · 2016

    Cited in: Dosing

    View study
  • Ventfort6 studies
    View page
    [1]

    Peptide Bioregulation of Cardiovascular Aging

    Khavinson VK, Ryzhak GA, Grigoriev EI · 2017

    View study
    [2]

    Bioregulatory Peptides and Vascular Wall Remodeling

    Khavinson VK, Linkova NS, Ryzhak GA · 2014

    View study
    [3]

    KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging

    Khavinson VK, Linkova NS, Ashapkin VV · 2023

    View study
    [4]

    Molecular Aspects of Anti-aging Effect of Short Peptides

    Khavinson VK, Linkova NS, Tarnovskaya SI · 2021

    View study
    [5]

    Peptide Bioregulation of Aging: Results and Prospects

    Khavinson VK, Linkova NS, Pronyaeva VE · 2022

    View study
    [6]

    Ventfort (A-3) Blood Vessel Peptide Bioregulator — product and dosing reference

    Firma Vita / St. Petersburg Institute of Bioregulation and Gerontology · 2024

    Cited in: Dosing

    View study
  • Vesilute6 studies
    View page
    [1]

    The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19

    Linkova N, Khavinson V, Diatlova A · 2023

    View study
    [2]

    Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides

    Ashapkin V, Khavinson V, Shilovsky G · 2020

    View study
    [3]

    Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro

    Lin'kova NS, Drobintseva AO, Orlova OA · 2016

    View study
    [4]

    Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease

    Khavinson VK, Lin'kova NS, Umnov RS · 2021

    View study
    [5]

    Peptide Bioregulation of Cardiovascular Aging

    Khavinson VK, Ryzhak GA, Grigoriev EI · 2017

    View study
    [6]

    Vesilute (ED dipeptide) bioregulator — dosing and protocol reference

    Peptide Database (Khavinson urogenital bioregulator reference) · 2024

    Cited in: Dosing

    View study
  • Vilon6 studies
    View page
    [1]

    KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging

    Khavinson VK, Linkova NS, Ashapkin VV · 2023

    View study
    [2]

    The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19

    Linkova N, Khavinson V, Diatlova A · 2023

    View study
    [3]

    Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line

    Avolio F, Martinotti S, Khavinson VK · 2022

    View study
    [4]

    Peptide Regulation of Gene Expression and Protein Synthesis in Organotypic Cultures

    Khavinson VK, Linkova NS, Kvetnoy IM · 2013

    View study
    [5]

    Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway

    Khavinson VKh, Rybakina EG, Malinin VV · 2002

    View study
    [6]

    Vilon Peptide (KE): Bioregulator dosing and protocol overview

    Project Biohacking (Khavinson bioregulator reference) · 2024

    Cited in: Dosing

    View study
  • VIP (Vasoactive Intestinal Peptide)6 studies
    View page
    [1]

    IV Vasoactive Intestinal Peptide (Aviptadil) in COVID-19 Respiratory Failure: 60-Day RCT Results

    Youssef JG, et al. · 2022

    View study
    [3]

    Therapeutic potential of VIP and its receptor VPAC2 in type 2 diabetes

    Hou X, et al. · 2022

    View study
    [4]

    Therapeutic potential of VIP and its receptors in neurological disorders

    White CM, et al. · 2010

    View study
    [5]

    Vasoactive intestinal peptide: a potential target for antiviral therapy

    He Y, et al. · 2022

    View study
    [6]

    Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (NCT04311697)

    NeuroRx Inc. / Relief Therapeutics; ClinicalTrials.gov · 2020

    Cited in: Dosing

    View study
    [7]

    Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

    Petkov V, Mosgoeller W, Ziesche R, et al. · 2003

    Cited in: Dosing

    View study
  • Xenin-255 studies
    View page
    [1]

    Xenin-Derived Peptides: Multifaceted Regulators and Therapeutic Innovations in Metabolic Diseases

    Gong B, et al. · 2025

    View study
    [2]

    Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders

    Craig SL, et al. · 2021

    View study
    [3]

    Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes

    English A, et al. · 2020

    View study
    [4]

    The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin

    Craig SL, et al. · 2021

    View study
    [5]

    Xenin-25 Amplifies GIP-Mediated Insulin Secretion in Humans With Normal and Impaired Glucose Tolerance but Not Type 2 Diabetes

    Wice BM, Reeds DN, Tran HD, et al. · 2012

    Cited in: Dosing

    View study
  • Ziconotide (Prialt)6 studies
    View page
    [1]

    Efficacy and safety of Cav2.2 blocker Ziconotide in pain: meta-analysis and systematic review

    Picañol J, et al. · 2025

    View study
    [2]

    Can Ziconotide Be Used to Replace Opioids? Clinical Experience in 5 Patients

    Canovas Martínez L, et al. · 2025

    View study
    [3]

    Selecting Neuromodulation Devices For Chronic Pain Conditions: A Narrative Review

    Wahezi S, et al. · 2026

    View study
    [4]

    Ziconotide as an Opioid Rescue: Economic, Clinical, and Subgroup Considerations

    Gan H, et al. · 2025

    View study
    [5]

    Recurrent Ziconotide-Associated Delirium and Psychosis: A Case Report

    Noe G, et al. · 2025

    View study
    [6]

    PRIALT (ziconotide intrathecal infusion) Prescribing Information

    TerSera / U.S. FDA · 2023

    Cited in: Dosing

    View study